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The National Institute for Working Life is Sweden’s national centre
for work life research, development and training.
The labour market, occupational safety and health, and work organi-
sation are our main fields of activity. The creation and use of
knowledge through learning, information and documentation are
important to the Institute, as is international co-operation. The
Institute is collaborating with interested parties in various develop-
ment projects.
The areas in which the Institute is active include:
• labour market and labour law,
• work organisation,
• musculoskeletal disorders,
• chemical substances and allergens, noise and electromagnetic
fields,
• the psychosocial problems and strain-related disorders in modern
working life.
Preface
The Criteria Group of the Swedish National Institute for Working Life (NIWL) has the
task of gathering and evaluating data which can be used as a scientific basis for the
proposal of occupational exposure limits given by the National Board of Occupational
Safety and Health (NBOSH). In most cases a scientific basis is written on request from
the NBOSH. The Criteria Group shall not propose a numerical occupational exposure
limit value but, as far as possible, give a dose-response/dose-effect relationship and the
critical effect of occupational exposure.
In searching of the literature several data bases are used, such as RTECS, Toxline,
Medline, Cancerlit, Nioshtic and Riskline. Also information in existing criteria documents
is used, e.g. documents from WHO, EU, US NIOSH, the Dutch Expert Committee for
Occupational Standards (DECOS) and the Nordic Expert Group. In some cases criteria
documents are produced within the Criteria Group, often in collaboration with DECOS or
US NIOSH.
Evaluations are made of all relevant published original papers found in the searches. In
some cases information from handbooks and reports from e.g. US NIOSH and US EPA
is used. A draft consensus report is written by the secretariat or by a scientist appointed
by the secretariat. The author of the draft is indicated under Contents. A qualified
evaluation is made of the information in the references. In some cases the information can
be omitted if some criteria are not fulfilled. In some cases such information is included in
the report but with a comment why the data are not included in the evaluation. After
discussion in the Criteria Group the drafts are approved and accepted as a consensus
report from the group. They are sent to NBOSH.
This is the 21st volume which is published and it contains consensus reports approved
by the Criteria Group during the period July 1999 to August 2000. These and previously
published consensus reports are listed in the Appendix (p 79). Technical editing for
printing was made by Karin Sundström.
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1Consensus Report for Antimony and
Antimony Compounds
December 8, 1999
This report is based primarily on a criteria document from the Nordic Expert Group
(6).
Chemical and physical data
Substance,
Formula
CAS No. Mol.
weight
Melting
point °C
Boiling
point °C
Solubility
(cold water)
Antimony, Sb 7440-36-0 121.75 630.5 1750 none
Antimony trisulfide, Sb2S3 1345-04-6 339.68
   as antimony orange 1345-04-6 339.68 550 ca 1150 none
   as stibnite 1317-86-8; 339.68 550 ca 1150 none
7446-32-4
Antimony pentasulfide, Sb2S5 1315-04-4 403.80 75 (disint.) – none
Antimony trioxide, Sb2O3 1309-64-4 291.50
   as senarmontite 12412-52-1 291.52 656 1550 (subl.) very low
   as valentinite 1317-98-2 291.52 656 1550 very low
Antimony tetroxide, Sb2O4 1332-81-6 307.52
   as cervantite 930 – very low
Antimony pentoxide,
Sb2O5, Sb4O10
1314-60-9 323.50 380, 930 –
–
very low
Antimony selenide,
Sb2Se3
1315-05-5 480.40 611 – very low
Antimony triiodide,
SbI3
7790-44-5 502.47 170 401 (disint.)
Antimony tribromide,
SbBr3
7789-61-9 361.48 96.6 280 (disint.)
Antimony trichloride,
SbCl3
10025-91-9 228.11 73.4 283 very high
Antimony pentachloride,
SbCl5
7647-18-9 299.00 2.8 79 (disint.)
Antimony trifluoride,
SbF3
7783-56-4 178.75 292 319 (subl.) very high
Antimony pentafluoride,
SbF5
7783-70-2 216.75 7 149.5 high
Antimony hydride,
SbH3 (stibine)
7803-52-3 124.78 -88 -17.1 low
Antimony potassium tartrate,
K2[Sb2(C4H2O6)2]x3H2O
28300-74-5 667.87 – – high
(subl.)=sublimates; (disint.)=disintegrates; ca=circa. Data in the table are from References 6, 8, 33, 35,
44 and 46.
2Antimony is a silver-white, brittle, hard, metallic element that is easily powdered
(53, 70). It occurs naturally in several minerals, including stibnite (53). It occurs in
valences of -3, 0, +3 and +5 (53). Pentavalent antimony has a tendency to become
trivalent antimony in acidic environments, and thus functions as an oxidant (70).
Antimony oxidizes slowly in damp air, forming a dark gray mixture of antimony and
antimony oxide (70). Oxidation may be more rapid if the metal is in the form of
airborne particles (51). When metallic antimony is burned in air, it forms a white
vapor – antimony trioxide – that smells like garlic. Antimony hydride (stibine) at
room temperature is a colorless gas with an unpleasant odor (70).
Occurrence, use
Antimony is widely used in alloys of lead, tin and copper to increase hardness (4, 6).
Metals containing antimony are used in automobile batteries, solder, cable sheathing,
electrodes, printing type and ammunition. Antimony with a high degree of purity is
used in semiconductors, in thermoelectric equipment and in the glass industry.
Antimony trioxide is used, for example, as a catalyst, a white pigment in paint, and in
the pharmaceutical industry for production of organic antimony salts. Antimony
trioxide combined with a halide is widely used as a fire retardant, especially in
textiles. Antimony trisulfide and/or antimony pentasulfide are used as pigments, in
fireworks, in matches and in vulcanizing rubber. Antimony trichloride can be used in
textile dyeing and in the chemical process industry. Organic antimony salts are used
medically to treat parasite infections (4, 6, 46, 49).
Uptake, biotransformation, excretion
Antimony and its compounds can be taken up from the digestive tract (2, 6, 15, 25,
43), but uptake of the inorganic antimony compounds with low solubility is probably
quite limited (3, 9, 27). Lung retention data from animal experiments indicate that
the more readily soluble antimony compounds are much more readily taken up by the
lungs (16, 20, 28, 51). In two studies with rodents, the portion of the total body
burden of antimony in the lungs was calculated with the help of isotope-labeled
antimony. It was found that <1% was in the lungs 2 hours after inhalation exposure
to an aerosol of trivalent or pentavalent antimony tartrate, whereas 35-50% of the
antimony was still in the lungs two days after inhalation exposure to antimony
trichloride (16, 20).
In vitro experiments with human blood have shown that trivalent antimony binds
to red blood cells much more readily than pentavalent antimony (66). Antimony
accumulated in the red blood cells of rats repeatedly exposed to antimony potassium
tartrate via drinking water; concentrations of antimony measured in organs were
much lower (spleen, liver >kidneys >brain, fat) (55). Localization in the red blood
cells and distribution to liver, spleen and kidneys are also reported in an inhalation
study in which animals were exposed to stibine (62). Accumulation of antimony in
thyroid was observed in rats after long-term oral exposure to antimony trioxide (27).
It has also been demonstrated in animal experiments that soluble antimony salts are
3secreted in milk, and can pass the placental barrier (25). Data on distribution of
antimony after uptake from occupational exposure are sparse. A study of smelter and
refinery workers in Sweden reports antimony levels in femurs that may indicate
some deposition of antimony in bone tissue (45). After oral intake of a water-soluble
antimony salt (a case of poisoning) the largest concentrations of antimony were
reported to be in liver, bile/gall bladder, and mucous membranes of the digestive
tract (43).
In man, the main excretion pathway for antimony is reported to be via the kidneys
(21), but antimony can also be excreted in feces, and an enterohepatic cycle has been
demonstrated (2). Animal data indicate that antimony (antimony trichloride) is
excreted in bile in the form of glutathione conjugate and in urine in inorganic form
(2). Rapid excretion of antimony in urine is described in a case report of acute
poisoning by antimony trichloride smoke (65). In another study, slow excretion was
observed in a worker with antimony pneumoconiosis: elevated antimony levels could
be detected in urine several years after termination of exposure (47). In a study of
battery production workers occupationally exposed to low concentrations (up to 0.04
mg Sb/m3, personal monitors) of antimony trioxide or antimony trioxide and stibine,
it was calculated that the half time for excretion in urine was about 4 days (39).
There was a significant correlation between Sb concentrations in air and in
blood/urine, and by linear extrapolation a rough estimate of biological exposure
equivalents was made: an air concentration of 0.1 mg Sb/m3 (as Sb in total dust)
should thus correspond to a urine concentration of 60 µg Sb/g creatinine and a blood
concentration of 50 µg Sb/liter (39). In another work, in which antimony in urine and
in the breathing zones (personal monitors) of workers producing inorganic penta-
valent antimony compounds was monitored, it is calculated that with 8 hours of
exposure to air concentrations around 500 µg Sb/m3 the Sb concentration in urine
increases by an average 35 µg/g creatinine (2).
Toxic effects
Animal data
The acute toxicity of the various antimony compounds varies considerably. The LD50
for antimony trioxide given orally to rats is reported in an older study (63) to be >20
g/kg. The reported LD50’s for oral administration of antimony pentachloride and
antimony trichloride (rats) are 1115 and 675 mg/kg respectively (1). One study (32)
reports deaths in mice 4-8 hours after 15 minutes of exposure to 30–50 ppm
(155–259 mg/m3) stibine. Stibine can damage red blood cells and cause hemolysis.
Guinea pigs exposed to 65 ppm (337 mg/m3) stibine for 1 hour had changes in blood
composition, hemoglobin in urine, anemia and oliguria (67). Lung damage and
edema (but not hemoglobinuria) were observed in dogs and cats after one hour of
exposure to 40-45 ppm (207-233 mg/m3) stibine (67).
Inhalation exposure to sparingly soluble inorganic antimony compounds has
caused changes in lung tissue – probably due to the irritating qualities of the dust –
and effects on the heart and eyes: higher doses have resulted in effects on the liver
and spleen (see Table 1). Slight changes in the lungs (including focal hemorrhages)
4are reported in a study in which rats were intermittently exposed to 3.1 mg/m3
antimony trisulfide over a period of six weeks. In the same study, ECG changes and
histopathological changes in the heart were observed after six to ten weeks of expo-
sure to 3.1-5.6 mg/m3 (7). In a long-term experiment in which rats were exposed to
0.06, 0.5 or 4.5 mg/m3 antimony trioxide (99.7% pure), inflammatory changes
(interstitial and granulomatous inflammation) and fibrosis were observed in lungs of
the high-exposure group 6 to 12 months after termination of exposure (51). This
study also reports indications of an increased incidence of lens clouding in all dose
groups (especially among the females), although no clear dose-response relationship
could be identified and the significance of this observation is unclear. In an un-
published study (Watt, 1983; cited in References 3 and 35) it is reported that lung
changes (including focal fibrosis, hyperplasia, increased lung weight, inflammatory
changes) were observed in female rats exposed by inhalation to 1.9 or 5 mg/m3
antimony trioxide for one year.
Changes in spleen and liver were observed after repeated exposure to 45 mg/m3
antimony trioxide (14). Rats given repeated intraperitoneal injections of antimony
potassium tartrate for three months developed liver damage (inflammation, fibrosis)
at dose levels of 3 mg/kg body weight or above (15). Another study reports mild,
reversible histological changes in the livers of rats given drinking water containing
5 ppm antimony in the form of antimony potassium tartrate (equivalent to about
0.6 mg/kg body weight/day) for 3 months (55).
Human data
Antimony is extremely irritating to the digestive tract. Acute symptoms of poisoning
after oral intake include stomach cramps, nausea, vomiting and diarrhea (43). Liver
and kidney damage have been noted in severe cases (43). Symptoms of less severe
poisoning (metallic taste in the mouth, slight stomach pain, difficulty swallowing)
are reported after ingestion of an unknown amount of antimony trisulfide. The
subject’s blood level in this case was 5.1 µg Sb/l a few hours after the intake (2).
Disturbances in the digestive system, chemical burns/irritation of skin and eyes,
and irritation of upper respiratory passages are reported in a study of some workers
who were briefly exposed (precise times not reported) to smoke/spray or vapor from
a leak in a closed processing system containing a solution of 98% antimony tri-
chloride in anhydrous hydrochloric acid (65). The concentrations of antimony
measured in urine of a few persons with stomach symptoms 1-2 days after the
exposure were 1-5 mg/liter. Air concentrations were estimated to have been up to
73 mg Sb/m3 and 146 mg HCl/m3.
Symptoms/effects on 69 of 78 smelter workers who were exposed to smoke
containing antimony oxide are reported in an older study (57). Nosebleeds/sores in
the nose and inflammatory changes in respiratory passages were common, and some
workers who became ill 2 to 12 hours after exposure to “high” air concentrations
were diagnosed with pneumonia. There were also a few cases of dermatitis. Several
of the most highly exposed workers also reported symptoms involving the digestive
tract and nervous system (dizziness, headache, "tingling") and one worker, who had
large amounts of antimony in urine (600 mg/l), had indications of kidney damage
5(albuminuria). Muscle pain was reported in a few cases. Measured air concentrations
of antimony varied considerably. Concentrations ranging from 0.9 to 71 mg/m3 in the
breathing zone, and from 0.4 to 23 mg/m3 around stationary monitors, were reported.
The average concentration was reported to be 10-12 mg/m3. The workers were also
exposed to arsenic (up to 5 mg/m3 in the breathing zone) and in some cases to
sodium hydroxide as well, and this may have contributed to the observed effects.
Irritation of respiratory passages from exposure to antimony has been reported in
several other studies. Some severe cases of pulmonary edema and chemical burns
were reported after exposure to antimony pentachloride during a production distur-
bance (no exposure data given) (12). Two studies report nasal irritation and recurring
nosebleeds in a few persons who were exposed to dust of metallic antimony and
dust/smoke of antimony trioxide, but exposure to other substances may have
contributed to these effects (11, 68). One of the studies (68) reports the antimony
concentrations in the breathing zone of a worker who had antimony dermatitis and
nosebleeds. His job involved crushing high-purity (99.86%) metallic antimony and
heating it together with other metals. The average antimony content in the breathing
zone (8 hours) was calculated to be 0.39 mg/m3. The average concentration for a
250-minute period was 0.67 mg Sb/m3. It is stated, however, that air concentrations
were probably much higher for brief periods (68).
Long-term exposure to dust of inorganic antimony compounds (especially
antimony trioxide) has been reported to cause pneumoconiosis (antimoniosis). It is
similar both clinically and roentgenologically to other types of pneumoconiosis, such
as miner's lung (26, 47, 48, 56). One study reports pneumoconiosis (verified by X-
rays) in 44 of 244 process workers at an antimony smelter (48). A later study (49)
reports that measurements made during the 1980s showed air concentrations of
around 0.5 mg Sb/m3 (time-weighted average), and states that they had previously
been much higher (49). This statement is supported by a work published in 1963
(47), which reports that air concentrations of antimony (average values) measured at
different places in the smelter were usually in the range 0.5-5.3 mg/m3. The
composition of the dust is not described, but the antimony was probably mostly in
the form of oxide. In another study (56) it is reported that pneumoconiosis (verified
by X-rays) was diagnosed in 51 smelter workers exposed for 9 years or more to
antimony trioxide (39-89%) and antimony pentoxide (2-8%) along with small
amounts of other substances including free silicon dioxide and arsenic trioxide (0.2-
6%). Measured dust concentrations were reported to range from 17 to 86 mg/m3.
Exposed persons experienced coughing and breathlessness, and some of them had
emphysema and inflammatory changes in lungs (chronic bronchitis, inflammation in
upper respiratory passages). More than one in four had conjunctivitis. The influence
of smoking on these symptoms is not taken up.
Medicines containing antimony can have toxic effects on the heart, and deaths
have been reported (5, 7, 49, 59, 70). It is not clear whether occupational exposure to
antimony can affect the heart. One study (7) concerns 125 workers who made
polishing discs, and were exposed to dust containing antimony trisulfide for periods
ranging from 8 months to 2 years. There were six sudden deaths in the group, all but
6one of which were ascribed to heart problems. The study reports ECG changes in 37
of 75 examined workers. In the 16 years before antimony was introduced there had
been only one death in that department (heart infarct). After the use of antimony
trisulfide was discontinued, no new deaths due to heart disease and no abnormal
increase in heart/circulatory problems were reported in the department, although the
ECG changes persisted in 12 workers. Air concentrations of antimony were reported
to range from 0.6 to 5.5 mg/m3, usually above 3 mg/m3. Whether the dust contained
arsenic or other substances is not mentioned. It is not possible to determine from this
study whether there is a cause-effect relationship between exposure to antimony
trisulfide and effects on the heart. In another study (9) of a few persons exposed to
extremely high concentrations (42-52 mg/m3) of high-purity antimony trisulfide dust
(<0.07% arsenic, <0.18% lead), it is reported that very little of the dust was absorbed
and that the exposed subjects had no symptoms of poisoning.
It is also impossible to draw any definite conclusions from the published epidemi-
ological studies of antimony smelter workers (37, 49, 60), since they were probably
exposed to arsenic, lead and other substances as well. One study (60) reports the
Standardized Rate Ratio (SRR) and 90% confidence interval (CI) for mortality due to
ischemic heart disease for smelter workers in comparisons with three different
control groups: 1.49 (90% CI=0.84-2.63), 1.22 (90% CI=0.78-1.89) and 0.91 (90%
CI=0.84-1.09). Another study reports that the number of deaths due to ischemic heart
disease was lower than predicted. A report of the results published in 1994 (37) gives
49 deaths vs. 60.5 predicted. (References 37 and 49 report different results.)
There are several reports of contact eczema due to occupational exposure to
antimony, particularly antimony trioxide (6, 47, 49, 56, 64, 68). The skin symptoms,
usually intense itching and a characteristic rash called “antimony spots,” develop on
exposed skin – especially sweaty skin in warm, damp surroundings. They usually
clear up rapidly after exposure is stopped (47, 56, 64, 68). Antimony trioxide can
also be skin sensitizing (13, 50).
Mutagenicity
Antimony trioxide, antimony pentoxide, antimony trichloride and antimony
pentachloride were negative in mutagenicity assays with E. coli and Salmonella (18,
38, 41), but two of four other in vitro studies (38, 41, 42, 52) report that antimony
trioxide, antimony trichloride and antimony pentachloride were genotoxic in tests
with bacteria. One work (10) reports that antimony triacetate increased viral
transformation of mammalian cells in vitro. In another in vitro test with mammalian
cells, antimony trioxide showed no mutagenic activity (18). A significant increase of
sister chromatid exchanges was observed in human lymphocytes and mammalian
cells exposed in vitro to antimony trioxide and antimony trichloride, but not
antimony pentoxide or antimony pentachloride (24, 41). Antimony trichloride was
also shown to induce micronuclei in tests with mammalian and human cells in vitro
(22, 23, 34). In another in vitro study with antimony trichloride, indications of DNA
strand breaks (but not DNA-protein crosslinking) were observed in mammalian cells
(23). Antimony trioxide induced chromosome aberrations in human lymphocytes in
7vitro (18). A significant increase in the number of cells with chromatid breaks was
observed in human leucocytes exposed in vitro to sodium antimony tartrate (54).
There are few in vivo studies. One study reports no significant increase of
chromosome deviations in bone marrow cells of mice given antimony trioxide in
single oral doses of 400-1000 mg/kg body weight (29). However, the same authors
report a dose-related increase in the incidence of chromosome deviations in bone
marrow cells – but no significant effects on gametes (sperm head abnormalities) – in
mice given antimony trioxide by gavage in doses of 400-1000 mg/kg/day for one to
three weeks. Animals in the highest dose group died after three weeks of exposure.
The daily doses of antimony were calculated to be 1/50, 1/30 and 1/20 of the LD50
(31). Neither of these reports (29, 31) contains information on the purity of the
substance. In a later study with similar doses, no indication of chromosome damage
(as micronuclei in bone marrow erythrocytes) was seen (18). The antimony used in
this study was 99.9% pure, and the mice were given either a single oral dose of
5 g/kg or daily doses of 400-1000 mg/kg for up to three weeks (18). The mice
showed no clinical indications of toxicity, but in the females given the single large
dose there was a transient reduction in the proportion of immature erythrocytes (18).
No indication of increased DNA repair was seen in hepatic cells of rats given
antimony trioxide in single oral doses of up to 5 g/kg (18).
DNA strand breaks were seen in the spleens of mice after oral administration of
1500 mg antimony trichloride/kg body weight (Ashry et al, 1988; cited in Reference
6). In another study, dose-dependent chromosome aberrations were seen in the bone
marrow cells of mice given antimony trichloride (purity not reported) in single oral
doses of 70-233 mg/kg body weight. The doses were calculated to be 1/10, 1/5 and
1/3 of the LD50 (30).
Potassium antimony tartrate (purity not given) was also tested in vivo for cyto-
genetic effects (19). Doses of 2, 8.4 or 14.8 mg/kg (the highest dose = maximum
tolerable dose, or LD5) were given to rats by intraperitoneal injection, either all at
once or spread over 5 days. There were significant increases of chromosome
aberrations at all dose levels and with both the acute (linear increase with dose) and
sub-acute (maximum effect at intermediate dose) exposures.
Carcinogenicity
No increase in the occurrence of tumors was seen in mice given drinking water
containing 5 ppm potassium antimony tartrate throughout their lives (61).
In one study (28), male and female rats (90 animals per group) were exposed to
either 45-46 mg/m3 antimony trioxide (0.004% arsenic) or 36-40 mg/m3 antimony
ore (mostly antimony trisulfide; 0.08% arsenic) 7 hours/day, 5 days/week for up to
one year, and killed at intervals up to five months after exposure was terminated. For
exposed females (both substances) there was an elevated incidence (p <0.001) of
various types of lung tumors. The lung tumors were observed after 41 to 72 weeks in
19/70 (antimony trioxide) and 17/68 (antimony ore) animals. No lung tumors were
found in the exposed males or in controls of either sex. The tumor incidences in other
organs were not significantly elevated in any group (28). A high incidence of lung
8tumors in female rats exposed to antimony trioxide was also reported in another
study (Watt, 1983; cited in Reference 35). The animals (females only – about 50 per
group) were exposed to either 5 mg/m3 (4.2 mg Sb/m3) or 1.9 mg/m3 (1.6 mg Sb/m3)
antimony trioxide (0.02% arsenic) 6 hours/day, 5 days/week for 13 months, and
killed up to 1 year after termination of exposure. Lung tumors were observed after
two years in 14/18 animals in the high-dose group, 1/17 in the low-dose group and
0/13 in controls. Lung tumors had also been observed in animals killed earlier: 6/16
in the high-dose group and 1/6 in controls. In 1988, the IARC concluded from these
studies that there is “sufficient evidence” that antimony trioxide is carcinogenic to
experimental animals and “limited evidence” that antimony trisulfide is carcinogenic
to experimental animals (35).
Another cancer study with laboratory animals has since been made. In this study
(51), rats (both sexes, 65 per group) were exposed to antimony trioxide concentra-
tions of 0.06, 0.5 or 4.5 mg/m3, 6 hours/day, 5 days/week for up to 12 months, and
then observed for up to a year. No elevation in tumor incidence was seen. A possible
explanation for the discrepancy between this study and the Watt study is that the
exposure levels in the Watt study were probably higher than reported (51).
There are very little reliable carcinogenicity data on humans. In 1988 the IARC
concluded that it could not be definitely determined whether antimony trioxide and
antimony trisulfide are carcinogenic to humans (35). In its overall assessment,
antimony trioxide was classified as “possibly carcinogenic to humans” (Group 2B),
whereas antimony trisulfide was “not classifiable” as to its carcinogenicity to humans
(Group 3).
Several epidemiological studies have since been published. In a British study
which followed its cohort from 1961 to 1992, there was an elevated incidence of lung
cancer in antimony process workers hired prior to 1961: 32 deaths due to lung cancer
vs. 14.7 predicted (p <0.001). For workers recruited after 1960, however, there was
no over-frequency of lung cancer: 5 deaths vs. 9.2 predicted (17, 37, 49). An article
published in 1963 (47) reports that average air concentrations of antimony at the
smelter were usually between 0.5 and 5.3 mg/m3 (rising to 37 mg Sb/m3 at one
location for short periods only). An American cohort study of smelter workers hired
between 1937 and 1971 (60) reports a trend to an elevated incidence of lung cancer
(Standardized Mortality Ratio (SMR) 1.39; 90% CI=1.01-1.88) and a significant
positive trend with longer time on the job. In this study it is reported that the air
concentrations of antimony at the smelter were between 0.1 and 2 mg/m3 (“8-hour
area samples”) when they were measured in 1975. An elevated risk of cancer in the
large intestine was identified in a Swedish study of workers in art glass production.
The workers had been exposed to inorganic antimony (no air concentrations given)
and several other substances (69). No definite conclusions on whether there is a risk
of cancer from antimony exposure can be drawn from these studies, since the results
may have been affected by numerous other factors including the presence of arsenic
(3, 6).
9Teratogenicity, effects on reproduction
No effects were seen in the fetuses of sheep given potassium antimony tartrate orally
in doses of 2 mg/kg body weight/day during gestation (36). In another reproduction
study (58), antimony trichloride was given in drinking water (0.1 or 1 mg/dl) to
female rats during gestation and for three weeks afterward, and to the pups from 22
to 60 days of age. The mothers in both dose groups had somewhat lower weight gain,
but no effects were seen on either litter size or length of gestation, and no mal-
formations were seen in macroscopic examination of the pups. Vasomotor reactivity
was tested in the pups at the ages of 1 and 2 months, and it was noted that there was a
dose-dependent reduction in the response triggered by l-noradrenaline, l-isoprenaline
and acetylcholine on day 60. The pups in the high-dose group also weighed
significantly less from 10 days of age.
There is a Russian study (Belyaeva, 1967; cited in Reference 6) of pregnancy
outcome and menstrual irregularities. The quality of the study has been questioned,
however, so no definite conclusions can be drawn from it (3, 6).
Dose-effect/dose-response relationships
There are few reliable workplace measurements of air concentrations of antimony,
and it is thus difficult to establish a direct dose-response relationship for occupational
exposure. There is also the problem of mixed exposures – especially arsenic – which
makes it difficult to isolate the effects of antimony. Several studies, however, have
reported pneumoconiosis and skin rashes (antimony spots) in persons occupationally
exposed to antimony dust/smoke. One work (49) reports that the proportion of
smelter workers with pneumoconiosis dropped below 4% when the work environ-
ment in the antimony smelter was improved, and that antimony spots also became
less common. The air concentration of antimony (8-hour average) at the smelter had
earlier been above 0.5 g/m3, and had been brought down to that level only a few
years previously. Another work (68) describes dermatitis in three workers which
could probably be ascribed to exposure to antimony trioxide smoke. Two of the three
also had recurring nosebleeds, but it is not clear whether they were due to the
antimony exposure. Their job involved work with metallic antimony of very high
purity (99.86%). The antimony exposure (8-hour averages, breathing zone) was
calculated for one worker to be 0.39 mg/m3. The average concentration for 250
minutes was 0.67 mg Sb/m3. It is also reported, however, that extremely high peaks
probably occurred (68). The dose-effect relationships observed in laboratory animals
exposed to antimony are summarized in Table 1.
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Table 1. Exposure-effect relationships observed in experimental animals exposed by
inhalation to sparingly soluble antimony compounds
Exposure Substance Species Effect Ref.
45-46 mg/m3, 7 hours/day,
5 days/week, up to 1 year
+ up to 20 weeks
observation
Sb2O3 Rat Lung tumors (females), lung
changes (including fibrosis,
metaplasia)(both sexes), slightly
reduced weight gain (males)
28
45 mg/m3, 2-3 hours/day,
7 days/week, 16 days-
30 weeks
Sb2O3 Guinea
pig
Lungs: inflammatory changes,
hemorrhages, increased weight.
Liver: fatty degeneration, increased
weight.
Spleen: increase in hemoglobin,
hyperplasia in lymph follicles.
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36-40 mg/m3, 7 hours/day,
5 days/week, up to 1 year
+ up to 20 weeks
observation
Antimony
ore –
mainly
Sb2S3
Rat Lung tumors (females), lung
changes (including fibrosis,
metaplasia)(both sexes), slightly
reduced weight gain (females)
28
32 mg/m3, 90 minutes Metallic
antimony
Rat Lung changes, including pinhead
hemorrhages, somewhat higher
lung weight.
40
28 mg/m3, 5 days Sb2S3 Rabbit ECG changes, slight to moderate
heart degeneration, inflammatory
changes in lungs, sight
degeneration in liver and kidneys.
7
24 mg/m3, 6 hours/day,
5 days/week, up to 13
weeks + up to 27 weeks
observation
Sb2O3 Rat Lower weight gain (males), higher
absolute and relative liver weights.
Fibrosis and inflammatory changes
in lungs during observation period.
51
5.6 mg/m3, 7 hours/day,
5 days/week, 6 weeks
Sb2S3 Rabbit
(males)
ECG indicated slight to moderate
damage to heart muscles,
degenerative changes in heart.
7
5.6 mg/m3, 7 hours/day,
5 days/week, 10 weeks
Sb2S3 Dog
(females)
ECG indicated some damage to
heart muscles, possibly slight
degenerative changes in heart.
7
5 mg/m3, 6 hours/day,
5 days/week, 13 months
+ up to 12 months
observation
Sb2O3 Rat
(females)
Lung tumors, elevated lung
weights, focal fibrosis, hyperplasia
and inflammatory changes in lungs.
3, 35
4.5 mg/m3, 6 hours/day,
5 days/week, up to 12
months + up to 12 months
observation
Sb2O3 Rat During observation period: fibrosis
and inflammatory changes in lungs.
51
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Table 1. Cont.
Exposure Substance Species Effect Ref.
3.1 mg/m3, 7 hours/day,
5 days/week, 6 weeks
Sb2S3 Rat
(males)
ECG changes in all exposed
animals, degenerative and very
slight inflammatory changes in
heart, slight lung changes
(including focal hemorrhages).
  7
1.9 mg/m3, 6 hours/day,
5 days/week, 13 months
+ up to 12 months
observation
Sb2O3 Rat
(females)
Lung changes: increased lung
weight, focal fibrosis and
hyperplasia, inflammatory changes.
 3, 35
Conclusions
Judging from the available data on occupational exposure to antimony, the critical
effect is its effect on the respiratory passages. Irritation of respiratory passages has
been reported to occur with short-term exposure to antimony, and pneumoconiosis
has been reported after long-term exposure to sparingly soluble antimony com-
pounds. Antimony compounds can also irritate eyes and skin, and cause contact
eczema. Epidemiological data indicate that there is an elevated risk of lung cancer
for persons exposed to antimony dust in smelters, but many other factors, notably the
presence of arsenic, may have contributed to the observed effect.
In experimental animals, the critical effect of antimony exposure is its effect on the
respiratory passages. Lung tumors have been observed in female rats exposed to
sparingly soluble antimony compounds (antimony trioxide, antimony trisulfide).
Antimony compounds have been shown to be genotoxic in vitro, but there is no
conclusive in vivo evidence of genotoxicity.
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Consensus Report for Potassium
Hydroxide
March 15, 2000
Chemical and physical data. Occurrence
CAS No.: 1310-58-3
Synonyms: caustic potash, potassium hydrate,
potash lye, potassa, potassa caustica
Formula: KOH
Molecular weight: 56.11
Boiling point: 1320°C
Melting point: 360°C
Vapor pressure: 1 torr at 719°C
Solubility in water: 1120 g/l at 20°C
Potassium hydroxide is produced by electrolysis of potassium chloride. It is a white,
hygroscopic solid, usually in the form of clumps, sticks or pellets. On exposure to
air, it absorbs water vapor and carbon dioxide and rapidly disintegrates to bicar-
bonate and carbonate. A 0.1 M solution has a pH of 13.
Potassium hydroxide is used in soap production, in paint removers and cleaners, in
galvanizing, in the photographic industry, and in production of other potassium
compounds (1). Potassium hydroxide may occur in air as either dust or aerosol.
There are no data on air concentrations.
Uptake, biotransformation, excretion
No data were found on uptake, biotransformation or excretion of potassium
hydroxide.
Toxic effects
Human data
There are several case reports of poisoning due to ingestion of household products
containing about 30% caustic potash (liquid lye), which caused severe damage to the
esophagus (8). Even one second of exposure to a very small amount of lye can be
enough to initiate necrosis.
There is a study of eye injuries due to industrial accidents with alkali (7), all of
them due to splashes. In nearly half the cases, the eye was hit by an alkali solution
under pressure. Most of the injuries occurred in the construction and chemical
industries.
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Animal data
For rats, the LD50 with oral intake is 214 to 1890 mg/kg (3, 6, 13). A 5% solution of
potassium hydroxide (0.1 ml) was applied to either intact or damaged skin of rabbits
and allowed to remain for 24 hours (6). The treatment resulted in mild irritation of
intact skin and severe irritation of damaged skin.
Rabbits and guinea pigs were used in another study (11): 0.25 ml of a 10% solu-
tion of potassium hydroxide was applied to intact or damaged skin and left for
4 hours. The treatment resulted in severe burns. In a later study (12), 0.5 ml of a 5%
or 10% solution of potassium hydroxide was applied to the skin of rabbits. Both
solutions were judged to be severely irritating and corrosive after 1 hour of treat-
ment.
To study the effects of potassium hydroxide on the esophagus, a cat was anesthe-
tized and the esophagus opened. An 8% solution was applied for 30 seconds and then
thoroughly rinsed off. After 2 hours extreme redness and fluid formation were noted
at the site of application. Underlying muscle was also damaged (2).
Potential for eye irritation was tested using potassium hydroxide solutions in the
concentration range 0.1 to 5%: 0.1 ml of solution was applied beneath the eyelid of a
rabbit and left for either 5 minutes or 24 hours, after which it was thoroughly rinsed
off. Five minutes of exposure to the 5% solution was "corrosive", whereas 5 minutes
or 24 hours of exposure to the 1% solution was "irritating". The 0.5% solution left for
24 hours caused only "marginal irritation", and the 0.1% solution had no effect (6).
Mutagenicity
In a test system with E. coli based on reverse mutation to streptomycin resistance,
no mutagenic effects were observed at potassium hydroxide concentrations up to
0.019% (4).
Cultures of hamster ovarian cells were used to assess chromosome damage from
alkali. In potassium hydoxide solutions without metabolic activation (S9 mix) there
was no chromosome damage in the pH range 7.3 to 10.9 (9). In the presence of the
S9 mix a few chromosomal aberrations appeared at pH 10.4 (12 mM potassium
hydroxide), and the frequency of aberrations increased with the amount of S9 added.
The proposed explanation was that chromosome-damaging substances were formed
by the breakdown of the S9 at high pH.
Carcinogenicity
In a cancer study, 3% to 6% solutions of potassium hydroxide were applied to the
backs of mice (29 males and 52 females). The treatment was repeated daily or every
second day until the first damage appeared, and thereafter about twice a week for 4
to 6 weeks. The total treatment time was 25 to 46 weeks. Tumors developed in 14%
of the males and 15% of the females. There were no controls (19). This study is
discussed by Ingram and Grasso (5). If tumors appear after the formation of sores
and epidermal necrosis, it is probable that they are not of genotoxic origin.
Substances that cause severe and repetitive skin damage can cause cancer by a non-
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genotoxic mechanism. It is unlikely that humans would repeatedly suffer skin
damage by alkali. Further, human skin is less sensitive than mouse skin (12).
Dose-effect/dose-response relationships
There are no data from which to derive a dose-effect or dose-response relationship
for occupational exposure to potassium hydroxide. Eye irritation has been studied in
rabbits. A 5% solution was corrosive to the eye, and a 0.1% solution had no effect.
When the substance was applied to the skin of laboratory rodents, a 5% solution was
highly corrosive. No NOEL (no observed effect level) has been reported.
Conclusions
There are no data that would serve to define a critical effect for occupational
exposure to potassium hydroxide. Since the substance is a strong base, the critical
effect is assumed to be irritation of eyes, skin and mucous membranes.
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Consensus Report for Chromium and
Chromium Compounds
May 24, 2000
This report is an update of the Consensus Report published in 1993 (71), and is based
primarily on the 1993 criteria document (58) and subsequently published research.
The Criteria Group also published a consensus report on chromium and chromium
compounds in 1981 (104).
Chemical and physical data. Occurrence.
chromium chromium trioxide
CAS No.: 7440-47-3 1333-82-0
Synonyms: metallic chromium chromium(VI) oxide
chromic acid anhydride
Formula: CrCrO3
Molecular weight: 51.00 99.99
Boiling point: 2482°C 230°C
Melting point: 1890°C 196°C
zinc chromate potassium dichromate
CAS No.: 13530-65-9 7778-50-9
Synonyms: zinc chromium oxide potassium bichromate
potassium dichromate(VI)
Formula: ZnCrO4 K2Cr2O7
Molecular weight: 181.37 294.18
Boiling point: (no information) 500°C
Melting point: (no information) 398°C
Chromium occurs naturally in the earth's crust in the form of chromite.
Chromium(III) oxide accounts for 15 to 65% of its metallic oxide content. Reduction
of chromite by the addition of carbon at high temperature results in the formation of
ferrochrome(0) and slag. Ferrochrome is used in the production of stainless steel and
other alloys. Heating the chromite with sodium carbonate and nitrate forms sodium
chromate, and this is the substance from which chromium compounds are obtained.
Chromium occurs in valences of –II to +VI. The hexavalent and trivalent forms are
those usually of concern with occupational exposure. Divalent chromium is
transformed to trivalent chromium on exposure to air or water. Quadrivalent and
pentavalent chromium are unstable transitional forms occurring when hexavalent
chromium is reduced to trivalent chromium (42).
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Table 1. Some chromium compounds and their chemical and physical characteristics (from
Reference 42)
Compound CAS No. Formula Mol. weight Solubility in water (g/l)
Hexavalent compounds
Barium chromate 10294-40-3 BaCrO4 253.33 0.0044 (28°C)
Lead chromate 7758-97-6 PbCrO4 323.18 0.00058 (25°C)
Calcium chromate 13765-19-0 CaCrO4 156.09 Low (no data)
Potassium chromate 7789-00-6 K2CrO4 194.20 629 (20°C)
Potassium dichromate 7778-50-9 K2Cr2O7 294.19 49 (0°C)
Sodium chromate 7775-11-3 Na2CrO4 169.97 873 (30°C)
Sodium dichromate 10588-01-9 Na2Cr2O7 262.00 2380 (0°C)
Strontium chromate 7789-06-2 SrCrO4 203.61 1.2 (15°C)
30 (100°C)
Zinc chromate 13530-65-9 ZnCrO4 181.37 Insoluble in cold water
Trivalent compounds
Chromium chloride 10125-73-7 CrCl3 158.36 Insoluble in cold water
Chromium nitrate 13548-38-4 CrN3O9 238.03 Dissolves in water
Chromium was discovered by Vauquelin in 1797. It is widely used in industry
because of its strength and hardness and the high resistance to corrosion provided by
the strong oxidizing nature of chromates. Chromium has been widely used in the
production of fireproof materials, in the chemical industry (as a catalyst), and in the
production of alloys, particularly stainless steel (e.g. 18:8 steel) and other special
steels (e.g. acid-resistant steels). Chromium is used for surface coatings, both chrome
plating, which results in a surface layer of metallic chromium, and chromating,
which provides a protective coating of chromates with various valences and degrees
of solubility. Hexavalent chromium compounds are used in many pigments and
chemicals. Chromates are used in wood impregnation (with arsenic and copper),
leather tanning and fireworks. Chromium trioxide was once used medicinally to treat
nosebleeds. Chromium(IV) oxide is used in production of cassette tapes.
A list of the chromium compounds mentioned in this report, with their valences,
CAS numbers, molecular weights and solubility, is presented in Table 1.
Hexavalent chromium. Hexavalent chromium is the substance of greatest concern in
the context of occupational exposure. According to a report from the National
Swedish Board of Occupational Safety and Health (1), occupational exposure to
chromium in Sweden affects 1000 steelworkers, several thousand welders, about
1000 chrome platers, several hundred in the paint and pigment industry, and 50
working with wood impregnation. In addition, there are a large number of construc-
tion workers who are exposed via cement. It has long been known that chrome
plating, pigment production and welding in stainless steel can be associated with
high exposures to hexavalent chromium, both in aerosol form and as particles in dust
and welding fumes. A summary made by the Swedish Board of Occupational Safety
and Health reports that in Sweden (up to 1993) air concentrations registered by
personal monitors were 1-8 µg/m3  around plating and 20-800 µg/m 3 around mixing
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and charging chromium pigments (1). With welding in stainless steel, the method
used determines how high the exposure can be: manual metal arc welding (MMA)
results in the highest air concentrations of both total chromium and hexavalent
chromium. Earlier studies have shown air concentration of hexavalent chromium
sometimes exceeding 100 µg/m 3 (58), and more recent studies have shown even
higher air concentrations - above 600-800 µg/m3 (73, 75, 98, 107). Elevated levels of
hexavalent chromium have not been found in the air around tungsten-inert gas
welding (TIG) (99), and there is no exposure to hexavalent chromium associated
with welding in mild steel (carbon steel).
Non-occupational exposure to hexavalent chromium may occur in environments
around textile dyeing, chrome plating and pigment industries, or around plants
making ferrochrome and stainless steel (78), or around incinerators handling tannery
waste (46). In New Jersey, slag containing hexavalent chromium has been used as
landfill in both commercial and residential construction (26). Non-occupational
exposure to hexavalent chromium can also occur via cement.
Trivalent chromium. Trivalent chromium is an essential trace element, and minute
amounts occur naturally in water and food. It participates in the regulation of
carbohydrate and fat metabolism, and is necessary for the proper functioning of
insulin (105). Occupational exposure to trivalent chromium may occur around
industrial processes in which hexavalent chromium is reduced to trivalent chromium.
There are no studies of occupational exposure that treat trivalent chromium sepa-
rately. Exposure to trivalent chromium may also occur via leather tanned with
chromium.
Uptake, biotransformation, excretion
For occupational exposure to hexavalent chromium, uptake via respiratory passages
is of greatest concern. Chromium compounds with high or moderate solubility are
absorbed more easily than compounds with low or no solubility. Particle size also
plays a role in chromium uptake by the body. Small particles of hexavalent chro-
mium like those in welding fumes penetrate deep within the lungs to the alveoli,
where they may be reduced to trivalent form in macrophages (74). Chromium that is
not absorbed remains in the lungs for a long time. In autopsy studies made during the
1980s it was found that elevated levels of chromium remained in lung tissues for
several years after occupational exposure had ceased.
Skin uptake of hexavalent chromium can also be relevant in occupational expo-
sures, as evinced by several case reports of renal and other systemic effects in
chrome platers following skin contact with chromic acid. In experiments designed to
measure body uptake via skin (volunteers took a 3-hour soak in bathwater containing
22 mg/l potassium dichromate, equivalent to the worst conceivable environmental
exposure) there were slight, transient elevations of chromium levels in plasma,
erythrocytes and urine (16). According to the authors, this was the first study that
showed systemic uptake in vivo, and the low chromium levels in blood and urine
were regarded as an expression of an effective reduction system in the skin. In in
vitro permeability tests in which human skin was exposed to various chromium
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compounds in a diffusion chamber, hexavalent potassium dichromate was taken up
more readily than the trivalent compounds chromium chloride and chromium nitrate
(33). It was noted that the hexavalent chromium was reduced in the skin to trivalent
chromium, but that the reduction capacity of skin in vitro was limited. The expla-
nation then proposed for the low skin uptake of trivalent chromium was that trivalent
chromium was bound to proteins in the dermis, forming stable complexes (4).
Hexavalent chromium is much more readily taken up from the digestive tract than
the trivalent form, and uptake is of comparable magnitude in experimental animals
and man (58). When water-soluble hexavalent chromium was taken orally by human
subjects, absorption was in the range 1-24% (13), compared with 0.4% for inorganic
trivalent chromium (chromium chloride) and 1.7-4.0% for organic trivalent chro-
mium (chromium picolinate) (35). When subjects drank 0.1 to 10 mg hexavalent
potassium dichromate in water, uptake in plasma and erythrocytes was seen in those
given 5 and 10 mg and elevated (dose-related) urine levels were observed in all of
them (27, 57). Hexavalent chromium can be reduced to trivalent form in the acid
environment of the stomach, which reduces absorption. Inter-individual variation in
reduction capacity has been noted in subjects given potassium dichromate (54). A
drink of orange juice increased the reduction capacity, resulting in lower and slower
absorption (53).
Hexavalent chromium has the same structure as the negative phosphate and sulfate
ions, and can therefore exploit the transport systems of these ions to cross through
the cell membrane into blood cells and other tissues. There are extra-cellular reduc-
tion systems (with ascorbic acid or glutathione, for example) in many tissues and in
blood plasma, which serve to reduce uptake and thus function as a detoxification
mechanism (15). Within the erythrocytes, the hexavalent chromium is rapidly
reduced to trivalent form via instable intermediates (quadrivalent and pentavalent
chromium) and bound to the globulin in hemoglobin (95-97%), other intracellular
proteins, and glutathione. The heme group then undergoes oxidation (54). Uptake in
the white blood cells follows a similar two-step pattern, and also involves a specific
transport mechanism that can become saturated (19). Most of the chromium taken up
in the hepatic cells is bound to glutathione in the cytosol, which protects the cell
from toxic effects. DNA damage requires passage of hexavalent chromium into a
nucleated cell and intra-cellular reduction via +V and +IV chromium to trivalent
chromium, which then penetrates the cell nucleus. This may halt the replication
process prematurely, or the cell may die, or it may become cancerous (62, 86, 100).
Trivalent chromium has no uptake mechanism in the cell. Uptake occurs slowly
via passive diffusion, perhaps aided by other processes also dependent on the
chemical structure of the ligands that may be bound to chromium (54). Trivalent
chromium is transported in the blood bound to serum albumin, various ß-globulins,
and other metal-transporting proteins such as transferrin.
Autopsy studies made in the 1980s showed not only high levels of chromium
remaining in lungs after occupational exposure from chrome plating or work with
chromates: high levels were also seen in lymph nodes, lung hilum, spleen, liver,
kidneys and heart (19).
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It has been demonstrated in animal studies that hexavalent chromium which is
inhaled or given by intratracheal instillation, as well as trivalent chromium injected
intravenously, is distributed by the blood to lungs, liver, kidneys, testes, spleen and
intestines (58). The chromium level in the spleen (unlike that in other organs) rises as
the blood cells containing chromium die and break down. Rats were given potassium
chromate in drinking water (100 ppm), and after six weeks of exposure the chro-
mium concentration was highest in the bones, spleen and kidneys, and lower in liver
and blood (101). Hexavalent chromium given parenterally to pregnant rats passes
through the placental barrier (42).
Inhaled hexavalent chromium is excreted primarily in urine. Chromium given
orally, as well as chromium that is trapped in mucus and swallowed, is excreted
primarily in feces. A small portion is excreted via skin and perspiration (13). Eleva-
ted levels of chromium have been measured in semen of welders who do metal arc
welding of stainless steel (6).
Half times. It has been shown that chromium distribution in the body has several
compartments, such as blood, with rapid turnover, liver and spleen with moderate
turnover, and other more compact tissues (such as bone) with slow turnover (27, 68).
The proposed half time for chromium in whole blood is 5.5 days, and the reported
half time for chromium in plasma is 4 days (19). The calculated half time for hexa-
valent chromium in urine (after oral intake of 5 mg potassium dichromate) is 39
hours (53).
The calculated half time for trivalent chromium in urine (after oral intake of 5 mg
chromium chloride) is 10 hours (53)
The half time for whole-body chromium in laboratory rats has been estimated to be
about 80 days (101).
Chromium levels in biological samples
It is difficult to establish a relationship between exposures to hexavalent chromium
and chromium levels in biological samples. The chromium level in whole blood is an
uncertain measure of chromium exposure. The chromium that has penetrated into an
erythrocyte remains there during the entire lifetime of the erythrocyte (115 days). In
studies of welders, a good correlation was found between chromium levels in air and
in erythrocytes (112, 113). Chromium levels in plasma reflect all types of chromium.
They rise rapidly during exposure and then quickly drop, and within a few days after
the exposure they have decreased to background levels (54). Blood is filtered in the
kidneys and the chromium is then excreted in urine. The chromium level in urine can
reflect exposure to both trivalent and hexavalent chromium, and has been used for
many years as a measure of occupational exposure (66). During the filtering process
in the kidneys, however, the chromium may be resorbed in the renal tubuli and re-
enter the blood; thus the urine level may also reflect the accumulation of chromium
in the body from previous exposures. The urine level is also affected by kidney
function and by the individual's ability to reduce hexavalent chromium to trivalent
form in plasma. A high extra-cellular reduction reduces uptake in the erythrocytes,
resulting in higher excretion in urine (74). These differences can make it difficult to
interpret measurements. Among metal arc welders exposed to chromium, smokers
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have higher urine levels of chromium than non-smokers even when they use
facemasks with air filters or Airstream helmets (98). Urine samples are used for
screening large groups of chromium-exposed workers. To determine an individual
worker's current exposure, however, urine samples must be taken before and after a
work shift (66).
Toxic effects
Human data
General effects.
The health effects of exposure to chromium are correlated to its valence and
solubility, and to the exposure pathway, exposure level, and particle size (17). It is
the hexavalent chromium compounds that are considered the greatest toxicological
hazard, although occupational exposure to trivalent chromium compounds may also
affect health.
Acute exposure to high levels may result in damage to the mucous membranes in
the digestive tract, vomiting and diarrhea, followed by liver and kidney failure. There
are several reported cases of death following intake of one gram of potassium di-
chromate, corresponding to about 350 mg hexavalent chromium (51, 97). Long-term
occupational exposure may result in eczema, open sores (chrome sores or chrome
ulcers), perforation of the nasal septum, chronic respiratory disease, kidney damage,
cancer, and effects on the immune system.
Skin
Eczema. Hand eczema was recognized as an effect of working with cement early in
the 1900s, and in 1925 Parkhurst identified the cause as contact with chromium salts
in the cement. In the 1950s, the methods of cement production were changed and the
amount of hexavalent chromium in cement increased. Jäeger and Pelloni identified
this as the cause of the marked increase of hand eczema subsequently observed
among cement workers (36). The chromium content of cement varies with the
production method and the raw materials used. In the Nordic countries, as in Great
Britain, cement has relatively high chromium content – up to 40 µg/g. In the United
States and Canada, cement has much lower chromium content and allergic contact
eczema is consequently much less prevalent among construction workers. A group of
Swedish dermatologists discovered that if iron sulfate was added to the cement its
chromate content was greatly reduced (32). Producers in Denmark began adding
iron(II) sulfate to cement in the early 1980s. Iron(II) sulfate in cement reduces
hexavalent chromium to trivalent chromium when water is added, and it brought the
content of soluble hexavalent chromium in the cement below 2 µg/g. Allergic contact
eczema due to chromate has since become much less prevalent among construction
workers (3). Iron sulfate has also been added to cement in Finland since 1987 and in
Sweden since 1989, with similar reductions in contact eczema due to chromate (83).
In Singapore the prevalence of chromate allergy dropped from 6.8% in 1986 to 2.7%
in 1992, after changes in the production process that reduced the chromium content
in cement by 60%, to 7.1 µg/g (36). In Great Britain, where no measures have been
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taken to reduce the chromate in cement, 17% of the construction workers employed
on the Channel tunnel had contact allergy to chromate (43). Contact allergy to
chromium can arise from occupational exposure not only to wet cement, but to
chrome plating baths and protective gloves of chromium-tanned leather, and in
production of pigments and dyes, printing, dry cleaning, leather tanning, and textile
dyeing (4). Contact with chromates in matches, wood ash, rust preventives,
galvanized steel, recording tapes, some green fabrics (e.g. military uniforms), and
chromium-tanned leather in shoes can also cause allergic contact eczema. Allergic
contact eczema due to chromate is widespread and often chronic (12, 31, 102, 109).
Allergic contact eczema due to chromate arises when soluble hexavalent chro-
mium compounds, which are readily absorbed by the skin, are reduced in the skin to
trivalent chromium which binds to proteins and activates the immune system,
causing sensitization (33). Contact allergy to chromate is identified by patch tests
(epicutaneous tests).
Many chromium compounds are sensitizing, and they can cause sensitization and
eczema in people who already have allergies. The usual cause of sensitization is
hexavalent chromium in cement. A person sensitized to hexavalent chromium also
reacts to trivalent chromium. Trivalent chromium compounds are much less
allergenic than the hexavalent ones because of their lower penetration, but in high
concentrations they can probably trigger allergic reactions. Metallic chromium is not
sensitizing because it has very low solubility and the chromate ions are therefore not
accessible to the skin (29).
Irritation and ulceration. Skin irritation and ulceration have been reported at an
average air concentration of 15 µg hexavalent chromium/m3  (4-74 µg/m 3) (70) (Table
3). Chrome sores can range in size from small, painful and persistent sores to large,
deep ulcers which with continued exposure pose a risk of increased chromium uptake
and severe systemic effects. Chrome sores used to be common in chromate factories,
particularly among new employees. The frequency has dropped with the years, as
changes in production methods have reduced exposure to hexavalent chromium and
hygienic routines have been improved (21).
Respiratory passage
Nose. Inhalation of chromate dust or vapor can cause nasal irritation, sores and
perforation of the nasal septum. Nasal irritation has been documented in chrome
platers exposed to chromic acid in air at levels of 1 µg/m3  or higher (65) (Table 3). In
the same study it was found that at average air levels of 2 to 20 µg/m3  33% of the
workers had nasal sores and 21% had perforated nasal septa. Later studies of chrome
platers have reported 48% with sores and 10% with perforated nasal septa at average
air concentrations (total chromium) of 11 µg/m3, and 68% with sores and 35% with
perforated septa at 28 µg/m3  (64) (Table 3). The authors calculated that there was a
50% risk of perforated nasal septum after 2.2 years of chromium exposure as a
plater, and 100% risk after 8.2 years, at air exposures of 50 µg Cr/m3. Production
processes were changed in the chromate production industry in Germany in the
1970s, and the chromic acid in the air was reduced to 12-73 µg/m3  (annual averages).
The prevalence of perforated nasal septa subsequently dropped from 30% to 4% (56).
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Lungs. Temporary reductions in the lung function parameters FVC (forced vital
capacity) and FEV1.0 (forced expiratory volume during one second) have been
observed among chrome platers exposed to average air concentrations of hexavalent
chromium in the range 2-20 µg/m 3. A reduction of FVC was also seen among
workers who had low chromium exposure but were also exposed to a mixture of
acids and metals (65). Chromium-exposed platers who developed asthma have had
positive reactions to a prick test with chromium sulfate (79). Asthmatic construction
workers exposed to cement have had positive reactions to inhalation provocation
with potassium dichromate vapor (but not cement dust), resulting in a 20% reduction
of FEV1.0 (61). Among chromate workers, elevated mortality due to chronic obstruc-
tive lung disease has been observed for those employed prior to the process changes
introduced in the 1960s, but not for those hired later (21). Stainless steel welding
with coated electrodes has been associated with development of asthma (55).
Elevated frequencies of respiratory symptoms have been noted among welders
exposed to hexavalent chromium while welding stainless steel or railroad tracks (88)
(Table 3). The symptoms increased at chromium concentration above 20 µg/m3  but
were not correlated to particle concentration. Only one of the 46 controls (a smoker)
had respiratory symptoms. Both elevated occurrences of respiratory symptoms and
lowered lung function have been documented after 25 years of welding in stainless
steel (91). Welders of mild steel and stainless steel (TIG and MIG methods), non-
smokers as well as smokers, have elevated incidences of respiratory problems such
as chronic bronchitis. No difference related to welding methods has been found,
possibly because subjects are usually not grouped according to chromium exposure
(10, 23, 28, 111).
Kidneys
Increased excretion of ß2-microglobulin, an indication of damage to proximal renal
tubuli, has been observed in chrome platers exposed to hexavalent chromium in
average air concentrations of 4-8 µg/m3 (67) (Table 3). Platers exposed to an average
air concentration of 4 µg/m 3 (0.4-183 µg/m3) total chromium, and with chromium
levels of 2.4 µg/g creatinine in urine (0.1-21 µg/g creatinine) had higher excretion of
ß2-microglobulin as well as N-acetyl-ß-D-glucosaminidase (NAG), an indication of
renal dysfunction (69) (Table 3). Renal effects in the form of elevated excretion of
retinol-binding protein in urine at urine chromium levels exceeding 15 µg/g creatin-
ine had been observed in earlier studies of men who had worked in chromate
production for seven years (30). The authors suggested that this level in urine was
probably the threshold for effects on renal tubules. Air monitoring showed chromium
levels that were usually below 50 µg/m3, though there were some peaks as high as
1000 µg/m 3 (Table 3). Elevated excretion of NAG and other enzymes was also noted
in ferrochrome workers who had over 15 µg chromium /g creatinine in urine, leading
the authors of this study also to propose a chromium level of 15 µg/g creatinine in
urine as the threshold for toxic effects on kidneys (110). It was also concluded that
ten years of exposure to hexavalent chromium causes kidney damage. No exposure
data/air monitoring data are given in this study. There is a case report describing a
plasma cutter in stainless steel with chronic interstitial nephropathy. The chromium
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level in the patient's blood was 59.6 nmol/l (about 7 times higher than the reference
value) and the urine level was a corresponding 13 µg/g creatinine. There was consi-
dered to be no explanation other than the chromium exposure (81). In a study of
stainless steel welders, slightly elevated levels of ß2-microglobulin were found in
those exposed to air concentrations a bit over 50 µg Cr/m3, resulting in a concen-
tration of 30 µg chromium/g creatinine in urine. No other effects on kidneys were
seen (107). In another study, welders in stainless steel were compared with welders
in mild steel, with former welders and with controls. The study showed renal effects
in the form of increased protein excretion in urine (albumin, immunoglobulin G,
transferrin and orosomucoid, but not ß2-microglobulin) in both groups of welders. No
changes could be found in the controls. The former welders showed only a slightly
elevated albumin excretion, suggesting the renal effects were at least partially
reversible (9).
Liver
Effects of hexavalent chromium compounds on the liver have been observed only at
extremely high exposures (97). There are no studies documenting effects on the liver
from occupational exposure to hexavalent chromium.
Immunotoxicity
In in vitro studies using cells from human bronchial epithelium, chromium exposure
has caused some activation of the immune system. Trivalent and hexavalent
chromium were about equally effective, probably because of intracellular
transformation of the chromium (84). Chromium added to lymphocytes resulted in
inhibition of the cell-mediated immune response (37).
Animal data
Skin. Potassium dichromate was assessed in a Guinea Pig Maximization Test to
determine its potential for inducing contact allergy (delayed skin hypersensitivity).
The induction concentrations were 0.5% intradermal and 1% topical, the test
concentration was 0.3%, and 8 of 15 animals were sensitized (63). In another study,
potassium dichromate was tested in a Guinea Pig Maximization Test (GPMT),
Cumulative Contact Enhancement Test (CCET) and Freund's Complete Adjuvant
Test (FCAT) using a multi-dose-response protocol. The highest proportions of sensi-
tized animals were 4 of 5 in the GPMT, 7 of 9 in the CCET, and 7 of 8 in the FCAT
(108).
Kidneys. The NOAEL (no observed adverse effect level) for acute effects on the
kidneys of rats after intraperitoneal injection was calculated to be 10 mg hexavalent
chromium/kg body weight (94).
Liver. Effects of hexavalent chromium compounds have been seen on the liver
only at extremely high exposures (103).
Immunotoxicity. Lung inflammation was observed in rats that were exposed by
inhalation to soluble potassium dichromate or insoluble barium chromate (about
350 µg/m 3) 25 hours per week for 2 or 4 weeks. There were greater numbers of
neutrophiles and monocytes in lavage fluid from the rats that had been exposed to the
soluble chromium (14). The total number of macrophages was unchanged, but the
27
function of lung macrophages regarding IL-1 and TNF-α liberation was inhibited in
the rats that had inhaled the soluble chromium compound. The formation of free
radicals was increased in the rats that inhaled the insoluble chromium compound.
The groups of rats that had been simultaneously exposed to ozone were not
observably different.
Teratogenicity
Human data
In the late 1970s, Shmitova reported an elevated incidence of pregnancy and delivery
complications in women who worked in chromate production. These results are
difficult to assess, since no exposure data are given. No more recent studies of
chromium-exposed women were found.
An elevated risk of spontaneous abortion was reported among women whose
husbands were welders working with stainless steel: OR 1.99 for arc welding (95%
CI 1.07-3.69), OR 1.71 for TIG welding (95% CI 0.84-3.39), and OR 1.1 for welding
in mild steel (95% CI 0.5-2.4) (8). The exact times of these miscarriages were not
given, which made the exposure data uncertain and left open the possibility of mis-
classification. A supplementary study was therefore made covering miscarriages in
medical records of the wives of 1715 stainless steel welders during the 1977-87
period. No correlation was found between miscarriage and having a husband who
was a welder. The possibility of early miscarriage, not requiring contact with medical
services, could not be excluded (40).
Studies of male fertility have been focused on welders, and the results have been
contradictory. Some studies report deterioration in semen quality, while in other
studies no such effect was observed. It has been proposed that it is the heat itself that
is behind the tendency to reduced fertility that has sometimes been seen in welders,
regardless of which method they use. There is often no exposure data, which makes
it impossible to determine whether there is a relationship between exposure to chro-
mium and reduced male fertility. No correlation has been found between chromium
in urine and semen quality, or between chromium levels in blood, semen quality and
sex hormone level (7, 41). In two studies of welders (stainless steel or mild steel) and
different welding methods (TIG, MIG/MAG, arc welding) no effects on sex hormo-
nes or semen quality were observed. The chromium levels in urine and blood were as
low as those of controls not exposed to metals, and in both studies the authors con-
cluded that the results might have been different if the chromium exposures had been
higher (6, 41).
No elevation in the frequency of birth defects or cancer has been seen in the child-
ren of welders of stainless or mild steel (8).
Animal data
It has long been known from animal experiments that hexavalent chromium can pass
through the placental barrier and exert toxic effects on the embryo or fetus – death,
retarded growth and skeletal anomalies (42). Female rats given potassium dichromate
in drinking water (250, 500 or 750 ppm) for three months before mating had lower
28
fertility and higher resorption of fetuses, and there were skin hemorrhages and
skeletal defects in the young of the rats given 500 or 750 ppm. These doses also had
a general effect on the mothers (50). When mice were given chromium in drinking
water (250, 500 or 750 ppm) during gestation they had a higher frequency of aborti-
ons, and at the two higher doses there were effects on growth, hemorrhages and
skeletal defects in the young (47). No general effects on the mothers were observed.
Mice were given 1000 ppm potassium dichromate (hexavalent) or chromium chlo-
ride (trivalent) in drinking water during gestation and lactation, and the young of
both groups had impaired reproductive function and fertility in adulthood (2).
It was shown in 1990 that hexavalent chromium has toxic effects on the reproduc-
tive systems of male rats: intraperitoneal injections of sodium chromate (1, 2, or 4
mg/kg) were given daily for 5 days (24), and two months later all the animals had
dose-related changes in testes and lower sperm counts. No such effects were obser-
ved with chromium chloride (trivalent chromium). In a subsequent long-term study,
rats were given 0.5 mg/kg sodium chromate intraperitoneally 5 days/week for 8
weeks. Effects of the treatment included reduced sperm motility and lower testo-
sterone levels. The changes were reversible (25).
Mutagenicity and genotoxicity
In its 1990 monograph, the IARC concluded that many hexavalent chromium
compounds with various degrees of solubility can cause mutations and DNA damage
in bacteria and in mammalian and human cells. Trivalent chromium can also be
genotoxic under certain conditions. The trivalent form, however, is considerably less
active than the hexavelent form, probably due to its lower degree of absorption.
Indications of chromosome damage were observed in an in vitro study in which
Chinese hamster ovary cells were exposed to trivalent chromium in the form of
chromium picolinate (95). It has been observed in several other in vitro studies that
trivalent chromium can form bonds with DNA and interfere with replication (11, 87,
90). When hexavalent chromium was added to cell cultures it was transformed to
trivalent chromium, forming in the process DNA adducts with mutagenic effects
(106). The experimental conditions of an in vitro study play a large role in deter-
mining the reactivity of the intermediates, which probably explains why results are
sometimes contradictory (96).
Studies of chromium-exposed workers have also reported contradictory results,
with increases of chromosomal aberrations and sister chromatid exchanges in some
studies that could not be confirmed in others. Several methods using biological
samples to trace the mutagenic effects of chromium on the individual have been
developed and tried in recent years. Blood samples have been used, since blood
contains nucleated lymphocytes and cells from the target organs for chromosome
damage are usually more difficult to obtain. Methods presently in use are based on
detection of changes in DNA, usually in the form of DNA-protein cross-links, sister
chromatid exchanges or DNA strand breaks, or on the formation of the oxidized
deoxynucleoside 8-hydroxy-deoxyguanosine (8-OHdG) as an expression of oxidative
stress (18, 74, 113). Lymphocytes from chromate workers exposed to hexavalent
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chromium (<10 µg/m 3, with occasional peaks up to 55 µg/m3) were examined in a
pilot study. The chromium-exposed workers had higher levels of chromium in blood
and urine than controls, but no increase in DNA strand breaks or 8-OHdG was seen
(34). In 1990, when the IARC published its monograph on chromium, evidence of
genotoxic effect on welders was still judged to be inconclusive. More recent studies
of stainless-steel welders (arc welding) have shown a significant increase in the
frequency of chromatid breaks at an average exposure of 35 µg hexavalent
chromium/m3 (0.6-252 µg/m 3) (44) (Table 3). Welders of stainless steel using other
methods (TIG, MIG/MAG), whose average measured exposure to hexavalent
chromium was 1.8 µg/m 3 (0.04 -12 µg/m 3) showed no increase in frequency of DNA
damage (45). Welders exposed to chromium and nickel (urine levels corresponding
to exposures of 70-80 µg CrO3/m3 and <100 µg Ni/m 3) showed a significant increase
in the frequency of DNA-protein cross-linking but no indications of DNA strand
breaks (82) (Table 3). In a later study of welders with higher exposure to chromium
and nickel (levels in erythrocytes corresponding to exposures of about 100 µg
CrO3/m3 and 300 µg Ni/m3), a significant increase in frequency of DNA strand
breaks was observed (112) (Table 3). In the first study, the frequency of sister chro-
matid exchanges was significantly lower in the welders than in controls, whereas in
the second study it was significantly higher. Since inconsistent findings regarding
chromatid exchanges had also been reported earlier, the authors discuss factors other
than chromium exposure that might conceivably have affected the findings: nickel
exposure, age, smoking and drinking habits etc. (112). They also discuss the satura-
tion effect in DNA-protein cross-linking observed earlier (18) in lymphocytes at a
blood content of 7-8 µg Cr/l (corresponding to exposure to 30 µg CrO3 /m3 air). As a
possible reason for the observation of more DNA-protein cross-linking with expo-
sure to lower chromium levels and more DNA strand breaks at higher exposures
(112), the authors suggest that if earlier theories are correct – that it is DNA-protein
cross-linking that is the primary cause of cancer - exposures below 50 µg/m3  may be
more hazardous than higher ones (112). Another widely spread hypothesis is that
high chromium levels are more harmful, since they afford the cell's repair system too
little time to repair the breaks in DNA strands.
Carcinogenicity
Human data
Lung cancer
Chromium has been suspected of causing cancer for 100 years, and over the past
century there have been numerous studies to clarify the connection. Both the valence
and the solubility of the chromium compound are relevant to its carcinogenic effect.
The IARC monograph on chromium published in 1990 (42) states that there is
“sufficient evidence” that the hexavalent chromium compounds associated with
chrome plating and production of chromates and chromate pigments are carcinogenic
to humans, and “limited evidence” of carcinogenicity for the chromium compounds
present in welding fumes and gases, but welding fumes were judged to be “probably
carcinogenic.” Metallic and trivalent chromium were not classified as carcinogenic,
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since there was no proof of their carcinogenicity to humans. A problem with many
studies is that they contain inadequate exposure data for chromium and asbestos and
no information on smoking habits, which makes any derived estimates of risk
uncertain. There are also problems with extrapolating data from animal experiments.
A review article published in 1993 (59) concludes that inhalation of hexavalent
chromium can cause cancer. Zinc chromate was considered especially potent, but
calcium chromate was also regarded as carcinogenic.
Chromate production. In the 1950s, it was noticed in the United States, Great
Britain, Japan, Germany and Italy that chromate workers had a greater than average
risk of developing cancer in the lungs or nose, and since then a large number of
epidemiological studies have been made. They show a clear correlation between
cancer mortality and work in chromate production. The mortality due to lung cancer
has dropped in recent years. In a British follow-up study (Table 2), the lung cancer
mortality was twice the adjusted national death rates among chromate production
workers in two factories who were hired prior to 1958-1960, when the production
process was modified and limestone was removed (21). In a third chromate factory,
which was closed down in 1966, lung cancer mortality was less elevated. Lung
cancer mortality was not elevated among workers hired after the process change.
This improvement was attributed to the absence of calcium chromate, which was no
longer formed during the production process, and to hygienic improvements in
working conditions. No monitoring data are given, and there is no information on
smoking habits or asbestos exposure. A similar process modification was made in
Germany in 1957-1963 (56), and was also followed by a drop in lung cancer
mortality (Table 2). The remaining elevation in risk was attributed to smoking and/or
exposure to asbestos. No data on exposure prior to 1977 are given because of
differences in analysis methods, but between 1977 and 1987 the measured annual
averages were in the range 12 to 73 µg Cr/m3 (56). When workers in an American
chromate factory built in 1971 were followed up in 1989 (Table 2) there was no
elevation in lung cancer mortality in the group of 353 workers who began work in
the chromate industry in 1971. There was, however, an elevation (3 of 5 lung cancer
cases) among the 45 workers who had transferred from another chromate production
factory where exposure to total chromium (measured by personal monitors) was 5 to
20 times higher (50 to 5670 µg Cr/m 3, compared to a maximum of 289 µg Cr/m3
with >99% of values below 50 µg Cr/m 3). The authors point out that the short
follow-up period covered by the study combined with its small size weakens the
results (80).
Chrome pigment production. Several epidemiological studies have reported an
elevated incidence of lung cancer among workers in the pigment production industry,
especially with production of zinc chromate (59). Exposure to lead chromate has also
been associated with elevated risk of lung cancer (59). In a Japanese cohort study
covering 666 workers in the chrome pigment industry, lung cancer mortality in 1989
was calculated for those who had been employed for at least a year between 1950
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Table 2. Epidemiological studies of lung cancer mortality in workers occupationally
exposed to chromium. The numbers of cases expected are derived from mortality in the
general population in the same areas. SMR = Standard Mortality Ratio
Studied population Cases
observed
Cases
expected
SMR
  (95% CI)
*(90% CI)
Ref.
Two factories with chromate
production Workers hired before
1958-60; 1422 subjects
175 88.97 1.97 21
Workers hired after 1960; 670
subjects
14 13.7 1.02
(0.56-1.71)
21
One factory with chromate
production Workers hired before
1965; 199 subjects
12 9.91 1.21 21
Two factories with chromate
production Workers hired before
1957-63; 739 subjects
66 32.27 2.27
(1.78-2.85)
56
Workers hired after 1957-63; 678
subjects
9 7.34 1.26
(0.58-2.38)
56
Chromate factory built in 1971
New employees;
353 subjects
2 2.1 0.97
*(0.17-3.06)
80
Workers transferring from
another chromate factory; 45
subjects
3 1.22/3 years’exp.
*(1.03-1.45)
80
Five factories with chromate
pigment production New hires
1950-75; 666 subjects
3 2.95 1.02
(0.21-2.98)
49
One factory with nickel/chrome
plating New hires 1946-75; 812
men950 women
men: 40
women: 15
25.41
8.57
1.57 (1.13-2.14)
1.75 (0.98-2.89)
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and 1975 (Table 2). The study found no elevation in risk of lung cancer associated
with exposure to chromates of zinc, lead or strontium. No exposure data are given
(49).
Chrome plating. Elevated mortality due to lung cancer among chrome platers
exposed to hexavalent chromium has been found in earlier studies (58), and has also
been found in a more recent follow-up study from Great Britain (Table 2), which
calculated mortality in 1995 for chrome platers who had worked for at least six months
between 1946 and 1975 (92). More than five years of occupational exposure to
hexavalent chromium (but also to some nickel) was correlated to an elevated risk of
death due to lung cancer (Table 2). It was estimated that prior to 1973 the air levels of
hexavalent chromium were probably above 25 µg/m3. Smoking habits are not covered.
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No elevation in risk was seen for plating workers exposed to nickel only (92). In a
later analysis based on these results, a risk estimate was calculated for lung cancer
among chrome platers: the relative risk ranged from 1.22 to 1.62, depending on which
defined confounding factors were present (93).
Ferrochrome. Earlier studies have not been able to establish whether ferrochrome
work involves an elevated risk of lung cancer (58). There is no recent study focused
on this question.
Welding. Hexavalent chromium compounds are formed during welding in stainless
steel. There are several studies of the relationship between development of lung
cancer and exposure to welding fumes from welding in stainless steel. A meta-
analysis of five studies revealed an elevated risk of lung cancer (OR 1.9; 95% CI 1.3-
2.9) when smoking and asbestos exposure were considered (89). In a case-control
study, in which the cases consisted of lung cancer patients and the controls were
drawn at random from the studied population, it was found that three of the cancer
cases, but none of the controls, had welded alloys containing chromium and nickel
for more than 6000 hours (48). It has been asserted that both welders who work with
stainless steel and those who work with mild steel have an elevated risk of
contracting lung cancer (5, 20, 38, 60, 72, 76). In 1997 Moulin published a meta-
analysis of 49 published epidemiological studies of welders (31 cohort studies and 18
case-control studies) (77). In the conclusion he observed that the relative risk of lung
cancer is 30 to 40% higher among welders than among the general population. The
analysis shows elevated risk for welders of both mild steel and stainless steel. The
analysis of the correlation between lung cancer and welding in mild steel is based on
four studies. In the two studies with the highest risk estimates, the workers' known
exposure to asbestos is not included in the calculations. In a follow-up study of
stainless steel welders working for at least five years between 1950 and 1965,
elevated lung cancer mortality was seen in a “high-exposure” group exposed to
hexavalent chromium, probably above 20 µg/m3  (75).
Nasal cancer
It has long been known that occupational exposure to hexavalent chromium carries a
risk of developing sinonasal cancer (42). A Nordic case-control study was made to
study nasal and sinonasal cancer and its correlation with various types of exposure.
These cancers were more common among welders exposed to chromium and nickel
(OR 3.3: 95% CI 1.1-9.4) (39). An elevated incidence of cancer in the nose or
sinuses (4 observed cases, 0.26 expected; SMR 1538) was seen in welders with more
than 20 years of employment and “high” exposure to hexavalent chromium
(estimated from job category). In the chromate industry, the elevation in risk
disappeared after the process changes in the 1960s. The accepted explanation was
that calcium chromate was no longer formed (21). Four cases of cancer in the nasal
region are described in a case report, all of them men employed at the same chromate
factory for 19 to 32 years (85). Three of the men had previously been treated for lung
cancer that developed after 6 to 15 years of work. No information is given on the
number of workers at the factory, the type of exposure or the smoking habits of the
33
patients. There are also studies in which no elevation in the risk of nasal cancer is
noted despite the higher risk of lung cancer (56).
Other cancers
Elevated risk of stomach and intestinal cancer has been noted in several studies of
workers occupationally exposed to chromium. It is reasonable to assume that it may
be attributed to particles of hexavalent chromium that are swallowed, exposing the
mucous membranes of the stomach and digestive tract (59). Elevated risks not only
for lung cancer, but for stomach and kidney cancer as well, have been observed
among welders (52). Despite the elevated risk of lung cancer, no elevation in
mortality due to gastrointestinal cancer has been seen among chromate workers
employed prior to 1965 (21).
Animal data
The IARC, in its 1990 monograph, stated that there is "sufficient evidence" that the
hexavalent compounds calcium chromate, zinc chromate, strontium chromate and
lead chromate are carcinogenic to laboratory animals; "limited evidence" that the
hexavalent chromium compounds chromium trioxide (chromic acid) and sodium
dichromate are carcinogenic to laboratory animals; "inadequate evidence" that
metallic chromium, barium chromate and trivalent chromium compounds are
carcinogenic to experimental animals; and "inadequate evidence" that welding fumes
are carcinogenic to laboratory animals. There are no subsequent studies either
supporting or contradicting these assessments.
Dose-response/dose-effect relationships
There are clear problems with deriving a reliable dose-response relationship for
hexavalent chromium, since exposure data is sparse even in recent studies. In
addition, there is often simultaneous exposure to nickel, asbestos and/or tobacco
smoke, making it difficult to distinguish the specific effect of chromium. As shown
by the summary in Table 3, bronchial irritation has been reported at chromic acid
levels of 1-2 µg/m 3 in air, and transient reductions in lung function parameters and
chrome sores in the nose have been reported at levels of 2-20 µg/m3 . Perforated nasal
septa are reported at exposures of 11 µg/m3 hexavalent chromium, and their fre-
quency rises with increasing exposure. At a total chromium level of 4-6 µg/m3 there
are effects on the kidneys, with increased excretion of NAG and ß2-microglobulin.
Renal effects have been observed among welders with urine chromium levels of
30 µg/g creatinine, and 15 µg/g creatinine has therefore been proposed as the
threshold value for renal toxicity. Identical exposures seem to give rise to different
chromium levels in biological samples from different individuals and also to
differences in the severity of the toxic effects. Elevated frequencies of chromatid
breaks have been observed in blood samples from stainless steel welders exposed to
35 µg/m 3 hexavalent chromium (0.6-252 µg/m3), elevated frequencies of DNA-
protein cross-linking at 70-80 µg/m3, and elevated frequencies of DNA strand breaks
at 100 µg/m3. The lung cancer incidence among workers exposed to chromium is
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Table 3. Reports on health effects other than lung cancer associated with occupational
exposure to chromium
Exposure (µg/m3) Exposure
situation
No. of
subjects
Observed effects Ref
Total Cr CrO3
1-1.9 Plating 19 16% w/observed nasal irritation
21% w/atrophy in nasal mucuos
membranes
65
2-20 Plating 24 Transient reductions in lung function
parameters;
50% w/nasal irritation
33% w/atrophy
21% w/perforated nasal septum
65
4
(0.4-183)
Plating 34 24% w/elevated NAG excretion
15% w/elevated ß2-microglobulin excr.
69
4-8 Plating 13 15% w/elevated ß2-microglobulin 67
11-20 Plating 5 60% w/elevated ß2-microglobulin
40% w/perforated nasal septum
67
11
(0.5-40)
Plating 29 48% w/chrome sores in nose
10% w/perforated nasal septum
64
15
(4-74)
Plating 17 59% w/nasal irritation
82% w/skin irritation
65% w/chrome sores (skin)
70
>20 Welding
stainless steel
37 35% w/respiratory symptoms 88
>20 Welding
railroad tracks
8 50% w/respiratory symptoms 88
28
(0.7-168)
Plating 31 68% w/sores in nose
35% with perforated nasal septum
64
<50
(usually)
Chromate
production
43 21% w/elevated excretion of retinol-
binding protein
30
64
(7-161)
Welding
stainless steel
52 17% w/elevated ß2-microglobulin 107
75
(7.5-422)
35
(0.6-
252)
Welding
stainless steel
42 Elevated frequency of chromatid breaks 44
70-80
(estimated)
Welding
stainless steel
39 Elevated frequency of DNA-protein
cross-linking
82
100
(estimated)
Welding
stainless steel
39 Elevated frequencies of DNA strand
breaks and sister chromatid exchanges
112
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lower today than it was thirty years ago, probably because process methods and
working conditions have been improved and exposure has been reduced. The Dutch
Expert Committee for Occupational Standards has recently concluded that 40 years
of exposure to 8 µg respirable hexavalent chromium dust/m3, with linear extra-
polation, yields an additional lung cancer mortality risk of 1.4 cases per 100 exposed
workers (22).
Conclusions
The critical effect of occupational exposure to hexavalent chromium is its irritation
of mucous membranes in the upper and lower respiratory passages. Mutagenic
effects have also been observed in blood samples from chromium-exposed welders.
Hexavalent chromium is corrosive to skin and mucous membranes, and skin contact
can also induce contact allergy. Asthma has also been described. Hexavalent
chromium is carcinogenic. Occupational exposure has been found to induce cancer in
lungs and nose. Hexavalent chromium has caused reproductive disturbances in
experimental animals.
Trivalent chromium can cause skin irritation and allergic contact eczema. There
are no data from which to determine a critical effect of exposure to trivalent
chromium, metallic chromium or other chromium compounds.
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Pentyl acetate has several isomeric forms, and they often occur in mixtures.
Industrial grade pentyl acetate consists mostly of 1-pentyl acetate (4). In this report
"pentyl acetate" is placed in quotation marks to indicate that the isomer(s) referred to
was not specified: in most cases, however, it is probably 1-pentyl acetate.
Chemical and physical data. Uses
1-pentyl acetate
CAS No.: 628-63-7
Synonyms: n-amyl acetate, 1-amyl acetate
Formula: CH3COO(CH2)4CH3
Boiling point: 149°C
Melting point: -70.8°C
Density: 0.879 g/ml (20°C)
Vapor pressure: 0.53 kPa (20°C)
Saturation concentration: 5230 ppm (20°C)
3-methylbutyl acetate
CAS No.: 123-92-2
Synonyms: isopentyl acetate, i-pentyl acetate,
isoamyl acetate, i-amyl acetate
Formula: CH3COO(CH2)2CH(CH3)2
Boiling point: 142°C
Melting point: -78.5°C
Density: 0.876 g/ml (15°C)
Vapor pressure: 0.53 kPa (20°C)
Saturation concentration: 5230 ppm (20°C)
2-methylbutyl acetate
CAS No: 624-41-9
Synonyms: (isoamyl acetate)*
Formula: CH3COOCH2CH(CH3)CH2CH3
Boiling point: 141-142°C
Melting point: -
Density: 0.880 g/ml (12.5°C)
Vapor pressure: -
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1-methylbutyl acetate
CAS No: 626-38-0
Synonyms: 2-pentyl acetate, 2-amyl acetate,
sec-amyl acetate,** 2-acetoxypentane
Formula: CH3COOCH(CH3)(CH2)2CH3
Boiling point: 134°C
Melting point: -78.5°C
Density: 0.864 g/ml (20°C)
Vapor pressure: 0.93 kPa (20°C)
Saturation concentration: 9180 ppm (20°C)
3-pentyl acetate
CAS No.: 620-11-1
Synonyms: 3-amyl acetate, 3-acetoxypentane
Formula: CH3COOCH(CH2CH3)2
Boiling point: 133°C
Melting point: -
Density: 0.871 g/ml (20°C)
Vapor pressure: -
1,1-dimethylpropyl acetate
CAS No.: 625-16-1
Synonyms: tert-amyl acetate,
2-methyl-2-butyl acetate
Formula: CH3COOC(CH3)2CH2CH3
Boiling point: 124.5°C
Melting point: -
Density: 0.874 g/ml (19°C)
Vapor pressure: -
For all the above isomers: Molecular weight: 130.18
Conversion factors: 1 ppm = 5.402 mg/m3 (20°C), 1 mg/m3 = 0.185 ppm (20°C)
* irregular name that may occur in older literature.
** "sec-amyl acetate" usually refers to this isomer, but not always.
Pentyl acetate at room temperature is a clear, colorless liquid with a characteristic
fruity odor (4, 13, 21). The odor thresholds reported in various studies range from
about 0.01 to 7 ppm for 1-pentyl acetate, and from 0.001 to 200 ppm for 3-methyl-
butyl acetate (2). Pentyl acetate is only slightly soluble in water, but the isomers
differ somewhat in this respect (6, 31). Pentyl acetate – especially 1-pentyl acetate
and 1-methylbutyl acetate – is used as a solvent for paints, imitation leather, printing
products, cellulose, furniture polish etc. (13). 1-Pentyl acetate has been used
medically as an anti-inflammatory agent (4, 6). In nature, 1-pentyl acetate has been
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identified in fruits, and 3-methylbutyl acetate occurs as a pheromone in certain
beetles (13).
Uptake, biotransformation, excretion
Pentyl acetate is readily absorbed in the lungs. One work (21) reports partition
coefficients of 92 for 1-pentyl acetate and 59 for 3-methylbutyl acetate in human
blood/air in vitro. Substantial uptake of pentyl acetate in liquid form can also occur
via the skin. Skin uptake has been calculated on the basis of physical data for 1-
pentyl acetate: the calculated rate of uptake via skin exposed to a saturated aqueous
solution of 1-pentyl acetate was 0.46 mg/cm2/hour (14). This is equivalent to about
35% of uptake from inhalation exposure to 100 ppm (525 mg/m3).
Pentyl acetate is hydrolyzed in the body to acetate (acetic acid), a substance
common in normal metabolism, and pentanol (amyl alcohol), and then further
biotransformed (4). In vitro data suggest that in the liver and respiratory passages of
experimental animals 1-pentyl acetate is rapidly hydrolyzed by carboxyl esterases
(10). Pentanol, which is a substrate for the enzyme alcohol dehydrogenase, is a
competitive inhibitor of ethanol metabolism (4).
Toxicology
Human data
In one study, ten volunteers with unimpaired sense of smell were exposed (nasal
inhalation) for 10 seconds to 0, 1.3, 4, 13 or 42 ppm "pentyl acetate." Two other
substances were also tested in this study. The subjects could detect the odor of
"pentyl acetate" at all concentrations. They also rated nasal irritation on a scale of 0
(none at all) to 100 (equivalent to the strongest irritation previously experienced).
Their ratings averaged about 4 for the control exposure, 10 for 1.3 ppm, 20 for
4 ppm, and 25 for the exposure to 42 ppm "pentyl acetate." The tidal volume of nasal
inhalation ("pentyl acetate") was reduced by about 50 ml at 1.3 ppm and 70 ml at
42 ppm (37). The authors regarded the reductions as significant at 4 ppm and above,
although no statistical analysis is presented. It is difficult to assess the results of this
study, since a) the effects of the exposures to "pentyl acetate" were not well desc-
ribed and it is not clear what caused the reduction in tidal volume, and b) there are
virtually no comparable studies of other air contaminants using this method. This
study has therefore not been taken into consideration in the assessment of the
irritating qualities of "pentyl acetate."
In other studies, anosmic subjects (with no sense of smell) were used to determine
the threshold value for nasal irritation (1, 9, 36). In one work, the threshold concen-
tration for 1-pentyl acetate was reported to be 1648 ppm. In this experiment, 4
subjects tested the substance by "sniffing" vapors of different concentrations sprayed
into the nostrils (1, 9). A threshold value of 266 ppm for "pentyl acetate" is reported
in an abstract (4 subjects, nasal inhalation) (36).
An older study in which ten persons were exposed in a chamber to "pentyl acetate"
for 3 to 5 minutes reports that some of them experienced slight throat discomfort
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(subjective assessments) at an air concentration of 100 ppm, and at 200 ppm most of
them reported throat irritation. Some subjects reported substantial throat irritation as
well as mild irritation of eyes and nose at this concentration, and at 300 ppm most of
them suffered eye and nose irritation. The majority judged 100 ppm to be the highest
concentration acceptable for an 8-hour workday (29). Slight irritation of respiratory
passages, eyes, nose and throat is also reported in another older study in which
subjects in an exposure chamber were exposed to 185 ppm 3-methylbutyl acetate for
5 minutes; at 1850 ppm the irritation was more pronounced, especially in the
respiratory passages (16). In an experiment made in the early 1900s, two subjects
were exposed to 925 ppm 3-methylbutyl acetate for 30 minutes. They initially
reported throat irritation, including some coughing, and later on they reported addi-
tional symptoms including eye irritation, nasal secretion, dry throats, tightness in the
chest and slight drowsiness (23).
Studies of workers occupationally exposed to pentyl acetate are scarce. There are a
few reports mentioning dizziness, faintness, drowsiness, coughing, nausea and
effects on the optic nerve, but no air concentrations are given (4, 18, 23). Irritation of
the conjunctiva, but no effect on the cornea, is reported in an Italian study of workers
exposed to "pentyl acetate" in the range 3750 to 15,000 ppm along with ethyl acetate
(4).
Animal data
Pentyl acetate has low acute toxicity, both when given orally and when applied to
skin. The LD50 for oral administration to rats and rabbits has been reported to be
between 6.5 and 16.6 g/kg (20, 22, 28, 35). For skin application of the mixed isomers
(24 hours, rabbits) the LD50 was reported to be >20 ml/kg (>about 17.4 g/kg) (35).
Descriptions of the effects of inhaled pentyl acetate on experimental animals
mention primarily irritation of eyes and respiratory passages and symptoms indi-
cating effects on the central nervous system (Table 2). The threshold concentration
for stimulation of the trigeminal nerve (irritation) in anesthetized rats exposed to
"pentyl acetate" was reported to be 252 ppm (34). The RD50 for 1-pentyl acetate (the
concentration causing a 50% reduction in respiratory rate, a measure of sensory
irritation in the respiratory passages) was reported to be about 1500 ppm in some
short-term experiments with mice (3, 8, 27; cited in 33), whereas the reported RD50
for 3-methylbutyl acetate (mice) is 1056 ppm (27; cited in 33). Irritation of eyes and
respiratory passages has also been observed in experimental animals after a minute
or so of exposure to about 2000 ppm 1-methylbutyl acetate or 3-methylbutyl acetate
(Table 2).
In order to elucidate the effects on the central nervous system, the locomotion and
behavior of mice were observed during 20 minutes of exposure to 500, 1000, 2000,
or 4000 ppm "pentyl acetate" (7). Significant reductions in activity and difficulty in
rousing the animals were noted at 4000 ppm. It was also reported that animals
exposed to 2000 or 4000 ppm were easy to remove after the exposure period because
they were lethargic. At exposure to 1000 ppm or higher there were mouth move-
ments, and tremor and muscle spasms were noted when the animals were handled.
Concentration-dependent effects on locomotion were noted during the exposures to
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the higher dose levels (which levels are not reported). Older studies report disturbed
balance in experimental animals after a few hours of exposure to various isomers of
pentyl acetate at air concentrations of about 3000-5000 ppm or higher (Table 2).
Effects other than those on the respiratory passages and central nervous system
have been reported in a few studies of 3-methylbutyl acetate and "pentyl acetate"
(Table 2). Some older studies report albuminuria, pathological changes in kidneys,
liver, spleen, heart and adrenals, and secondary anemia in experimental animals
repeatedly exposed to air concentrations of 1850 to 4800 ppm (16, 31). These studies
were not made in accordance with modern praxis, and the validity of the results is
thus difficult to judge. An EU document (13) reports that "metabolic imbalance in
the liver" was observed in rabbits exposed to 1850 ppm "pentyl acetate" 2 hours/day
for 120 days. No further details of this study are given and the source of the infor-
mation is obscure. An Italian study cited in the Swedish criteria document (4) reports
that effects on the liver were noted in histological examination and serum enzyme
analyses of rabbits that had been exposed to 4300-5600 ppm "pentyl acetate"
1 hour/day for 50 weeks. In a study with guinea pigs, 750 or 1500 mg/kg of
undiluted 1-pentyl acetate injected into the abdominal cavity resulted in elevated
activity (dose-dependent) of the enzyme ornithine carbamyl transferase (OCT) in
serum, and histopathological examination revealed moderate fat deposition in the
liver in the low-dose group (three of four animals in the high-dose group died). The
authors concluded that 1-pentyl acetate has relatively low hepatotoxicity (12).
Damage to the corneal epithelium – no longer visible after a day or so – was
reported when liquid "pentyl acetate" was applied to the eyes of rabbits for 2 minutes
(18). Slightly reddened mucous membranes and watery eyes were reported in another
study (16) in which 3-methylbutyl acetate was dropped into the eyes of rabbits. In a
standardized test for eye irritation using rabbits, "pentyl acetate" was ranked 2 on a
ten-point scale (35) and in the same study minor indications of local irritation
(ranked 3 on the scale) were noted when undiluted "pentyl acetate" was applied to
the skin of rabbits (35). Undiluted pentyl acetate (60% 1-pentyl acetate, 35% 2-
methylbutyl acetate and 5% 3-methylbutyl acetate) applied to the skin of guinea pigs
and left for 24 hours under occlusion caused minimal irritation. The results of the
Guinea Pig Maximization Test indicated that this mixture might also possibly be
somewhat skin-sensitizing (5).
Mutagenicity, carcinogenicity, effects on reproduction
In in vitro tests with various strains of Salmonella typhimurium, both with and
without metabolic activation, 3-methylbutyl acetate had no mutagenic effect, and it
induced no DNA damage when tested in vitro on B. subtilis and E. coli (19, 26, 38,
39). No mutagenicity/genotoxicity was observed when 3-methylbutyl acetate was
tested on Saccharomyces cerevisiae (25, 40), and results were also negative when it
was tested for mutagenic activity or chromosomal aberrations on mammalian cells in
vitro (19, 26). It is also reported that no mutagenic activity (gametes) was observed
when 3-methylbutyl acetate (>99% pure) was given to Drosophila orally (4800 ppm
in diet), or via injection (14,000 ppm; 14 mg/g solvent) (17). In a study in which
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grasshopper embryos were exposed to vapor of "pentyl acetate" (air concentration
not reported), cytogenetic assays revealed no effects on mitosis (24).
There are no carcinogenicity data for any of the isomers.
Data on reproduction toxicity are also extremely sparse. From an in vitro test with
hydra cells, it was concluded that the embryonic cells were no more sensitive than
maternal cells to the toxic effects of "pentyl acetate" and 3-methylbutyl acetate (30).
In addition to this study, there are two unpublished papers (Union Carbide, 1994 a, b)
which are cited in the German threshold limit document (11). In these studies rats
and rabbits were exposed to 500, 1000, or 1500 ppm pentyl acetate (65% 1-pentyl
acetate and 35% 2-methylbutyl acetate) 6 hours/day on days 6-15 (rats) or 6-18
(rabbits) of gestation. On the basis of these studies 1-pentyl acetate and 2-methyl-
butyl acetate were judged to be not damaging to fetuses of rabbits exposed to 1500
ppm and rats exposed to 500 ppm (11). Somewhat lower fetal weights and elevated
incidences of some variations (including incomplete inflation of alveoli, effects on
ossification) were noted in fetuses of the rats exposed to 1000 and 1500 ppm (11).
Dose-effect/dose-response relationships
There are no data on occupational exposure that can be used as a basis for describing
a dose-response or dose-effect relationship for pentyl acetate. Several studies,
however, report irritation of mucous membranes in the respiratory passages and eyes
of subjects exposed to pentyl acetate in exposure chambers (Table 1). In an older
study, slight throat discomfort was reported by some of the subjects exposed to 100
ppm "pentyl acetate" for 3 to 5 minutes in an exposure chamber. Lower air concen-
trations were not reported. Moderate throat irritation and slight irritation of eyes and
nose were reported at 200 ppm, and it is stated that a majority of the subjects expe-
rienced throat irritation at this air concentration. At 300 ppm, most of the subjects
reported irritation of eyes and nose as well (29). In another older study (16), some
subjects reported mild irritation of eyes, nose, throat and respiratory passages after
5 minutes in a chamber containing 185 ppm 3-methylbutyl acetate, and at an air
concentration of 1850 ppm (5 minutes) the subjects reported moderate irritation of
eyes, nose, throat and respiratory passages, with symptoms including cough, chest
tightness, shallow breathing and watery eyes (16). Available data do not allow a
potency ranking of the different isomers.
Dose-effect relationships observed in laboratory animals exposed by inhalation to
the different isomers of pentyl acetate are summarized in Table 2.
Conclusions
The critical effect of exposure to pentyl acetate is judged to be irritation of the
respiratory passages, which has been reported by people briefly exposed to air
concentrations of 100 ppm or higher. There are no reliable studies of lower
exposures. The available data do not allow individual assessments of the isomers.
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Table 1. Effects on human subjects experimentally exposed to vapor of pentyl acetate
Exposure Isomer Effects Ref.
2000 ppm, brief 1-methylbutyl
acetate
"extremely unpleasant" 32
1850 ppm,
5 min.
3-methylbutyl
acetate
moderate irritation of airways, eyes, nose, throat
(cough, chest tightness, shallow breathing, watery eyes)
16
1648 ppm,
2 seconds
1-pentyl
acetate
threshold for nasal irritation. 1, 9
925 ppm,
5 or 30 min.
3-methylbutyl
acetate
irritation of throat and eyes, nasal secretion, dry throat,
chest tightness, slight drowsiness
23
266 ppm "pentyl
acetate"
threshold for nasal irritation with nasal breathing 36
200 ppm,
3 to 5 min.
"pentyl
acetate"
throat irritation in majority of 10 subjects, mild eye and
nose irritation in a few of them
29
185 ppm,
5 min.
3-methylbutyl
acetate
slight irritation of respiratory passages, eyes, nose and
throat
16
100 ppm,
3 to 5 min.
"pentyl
acetate"
slight throat discomfort in a few of 10 subjects 29
Table 2. Effects on experimental animals exposed to pentyl acetate by inhalation
Exposure Isomer Species Effects Ref.
7500 ppm
2 hours/day
60 days
"pentyl
acetate"
rabbit some degeneration of optic nerve  4, 18
5000 ppm
13 hours 30 min.
1-methylbutyl
acetate
guinea pig eye and nose irritation after 1 min.; tear
flow after 5 min.; loss of muscular
coordination after 90 min; narcosis after
5 to 9 hours, slight hemorrhaging in
lungs
 32
4300-5600 ppm
1 hour/day
50 weeks
"pentyl
acetate"
rabbit liver damage   4
4800 ppm
1 hour/day
40 days
"pentyl
acetate"
rabbit inflammatory changes in respiratory
passages, kidney damage, changes in
spleen, liver and heart, anemia
 31
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Table 2. Cont.
Exposure Isomer Species Effects Ref.
4700 ppm
2 hours/day
4 days
"pentyl
acetate"
guinea pig inflammatory changes in respiratory
passages, kidney damage, hepatitis,
changes in adrenals and spleen
 31
4400 ppm
6 hours 45 min.
3-methylbutyl
acetate
cat watery eyes, salivation, disturbed
balance after 2-3 hours, deep narcosis
after 5-6 hours
 16
4000 ppm
20 min.
"pentyl
acetate"
mouse reduced activity, pronounced lethargy,
effects on locomotion, tremor, spasms,
eye irritation
 7
2850 ppm
6 hours
3-methylbutyl
acetate
cat watery eyes, salivation, disturbed
balance after 5 hours 35 min.
16
2000 ppm
13 hours 30 min
1-methylbutyl
acetate
guinea pig nasal irritation after 1 min., eye
irritation after 1 to 30 min.
 32
2000 ppm
20 min
"pentyl
acetate"
mouse effects on locomotion, tremor, spasms  7
1850 ppm
2 hours/day
120 days
"pentyl
acetate"
rabbit "metabolic imbalance in the liver"  13
1850 ppm
8 hours/day
6 days
3-methylbutyl
acetate
cat watery eyes, salivation, inflammatory
changes in respiratory passages,
indications of kidney damage, cirrhosis
 16
1850 ppm 3-methylbutyl
acetate
cat immediate coughing and irritation of
mucous membranes in eyes, nose and
mouth
15
1562 ppm, 5 min. 1-pentyl
acetate
mouse RD50  33
1531 ppm, 10
min.
1-pentyl
acetate
mouse RD50  33
1438 ppm, 30
min.
1-pentyl
acetate
mouse RD50   8
1056 ppm, 5 min. 3-methylbutyl
acetate
mouse RD50  33
1000 ppm, 20
min.
"pentyl
acetate"
mouse tremor/shaking, spasms   7
252 ppm, 10
seconds
"pentyl
acetate"
rat threshold concentration for stimulation
of trigeminal nerve
 34
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Consensus Report for Wood Dust
June 25, 2000
This report is based on the criteria document previously published in Arbete och
Hälsa (9), two subsequently published critical reviews of the international literature
(8, 43), and research published in 1986 –1998. The text contains a number of
abbreviations, which are defined in Appendix 1.
Introduction
Wood dust is usually divided into two types: softwood and hardwood (29). In
general, the first type comprises conifers, and includes the spruce (Picea), pine
(Pinus) and larch (Larix) of northern latitudes as well as cedar (Cedrus,
Chamaecyparis, Thuja), cypress (Cupressus), hemlock (Tsuga) and redwood
(Sequoia). The hardwoods include deciduous trees such as ash (Fraxinus), aspen
(Populus), birch (Betula), beech (Fagus), oak (Quercus) and cherry (Prunus), as well
as tropical trees such as the mahogany family (Meliaceae) and teak (Tectona). The
types most widely used in the Swedish wood processing industry and in wood-
working classes in schools are spruce, pine, ash, aspen, birch, beech, oak, cherry,
abachi (Triplochiton scleroxylon), jelutong (Dyera costulata), mahogany and teak.
A list of the Latin and popular names of most of the softwoods and hardwoods
mentioned in this report is given in Appendix 2.
Chemical characteristics
Wood consists primarily of cellulose, hemicellulose and lignin. Some kinds of wood
contain other substances (extractants), which are usually sorted into three main
groups: aliphatic substances (mainly oils and waxes), terpenes, and phenolic
substances. Wood may also contain small amounts of minerals, proteins, acids,
alkaloids, and carbohydrates such as glucosides and saponins.
Physical characteristics
Wood particles vary in size and shape. The size of the wood particles generated
during processing depends on such factors as the type of wood, its water content and
the processing method. Hardwood dust is usually finer than softwood dust, and its
respirable fraction (see below) is thus usually greater (43).
Sampling wood dust
An individual’s exposure to wood dust is measured by outfitting the person with a
pump connected by a plastic tube to a special cassette containing a filter 37 mm in
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diameter. The amount of dust collected on the filter is weighed, providing a measure
of the amount of dust the person is exposed to. This measure is called the total dust
concentration, or   total dust  . Sweden has now adopted a new international standard
for dust measurement, SS-EN 481 (53), which defines the following categories:
inhalable dust = the total amount of airborne particles that can be inhaled through
the mouth and nose. These particles are up to 50-100 µm in size.
thoracic fraction = that portion of the inhalable particles that passes the larynx.
These particles are <10 µm in size.
respirable fraction = that portion of the inhalable particles that penetrates to the
parts of the respiratory passages that lack cilia. The particle size is <4 µm.
Different types of filter cassettes are used for measuring total dust and measuring
inhalable dust in accordance with the new standard. Consequently, in parallel
measurements of the same person made with the different methods, the total dust
value obtained may be lower than the measured concentration of inhalable dust.
Assessments of the correlation between exposure and effects on health are
currently based on total dust values. In the future, it is likely that health effects will
be related to dust concentrations established with other sampling methods.
Air concentrations of wood dust around work with wood
Exposures to wood dust at sawmills and joinery shops in various countries are shown
in Table 1.
For 48 workers at four different Swedish sawmills processing dry pine (12),
exposure to pinewood dust, measured as total dust, ranged from 0.1 to 1.1 mg/m3
(GM=0.3 mg/m3). For 38 carpenters at four different joinery shops in Sweden,
exposure to pinewood dust, measured as total dust, ranged from 0.1 to 4.6 mg/m3
(11). Exposure to wood dust during different operations in wood processing
industries in Sweden has recently been surveyed (34). The highest exposures were
measured around sawing (0.2-4.1 mg/m3), inspection (0.4-5.6 mg/m3) and finishing
(0.3-7.3 mg/m3). Of 125 whole-day averages, 16% exceeded the exposure limit of
2 mg/m3. The workers were monitored with the total dust and inhalable dust methods
simultaneously, and the readings for inhalable dust were about three times as high as
those for total dust.
In a study of 200 workplaces in the Danish wood and furniture industry, it was
found that sanding by hand generated the highest total dust concentrations, with a
geometric mean (GM) of 3.71 mg/m3. A combination of turning, surface grinding
and cross-cutting also yielded relatively high concentrations (GM=1.42-1.68 mg/m3).
In this study, a total of 752 total dust measurements were made with personal
monitors (60). Exposure to inhalable dust was measured with personal monitors at
seven wood processing businesses in England (21): exposures ranged from 0.3 to
55.2 mg/m3. A Dutch study (49) reports exposures to inhalable wood dust during
different operations in two joinery shops and a furniture factory. Whole-day
measurements were made – 199 with personal monitors and 164 with stationary
monitors. Sanding produced the highest exposure (>5 mg/m3). Other tasks producing
relatively large amounts of dust were sawing, routing and sweeping up.
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Table 1. Air concentrations (mg/m3) of wood dust measured by personal monitors in
sawmills and joinery shops in various countries. (T = total dust; I = inhalable dust; GM =
geometric mean)
Country Range Dust type Ref.
Sweden (1996, 1997) 0.10-4.6 (T) Softwood 11, 12
Sweden (1997) 0.10-7.30 (T) Softwood, hardwood 34
Denmark (1993) 0.51-3.71 (T) (GM) Softwood, hardwood 60
England (1991) 0.30-55.2 (I) Softwood,hardwood 21
Netherlands (1995) 0.82-9.79 (I) (GM) Not reported 49
Canada (1994) <0.08-52.0 (T) Softwood 55
Personal monitors were used to measure exposure to wood dust around sawing of
floated (wet) logs at two Canadian sawmills; they showed an average exposure of
0.51 mg/m3 (<0.08-52 mg/m3). Of the 237 total dust samples taken in this study, 85
(36%) were below the detection limit of 0.08 mg/m3 (55).
No studies were found relating the size distribution of wood dust particles to either
the type of workplace or the task being performed.
Uptake, distribution, excretion
The literature contains no studies, either human or animal, on uptake, distribution or
excretion of wood dust.
Toxic effects
Animal data
In patch tests with guinea pigs, extracts from the softwoods Western red cedar (Thuja
plicata), Douglas fir (Pseudotsuga menziesii) and hemlock had different sensitizing
potential. However, the sensitizing potential was found to be dependent on the
solvent used for extraction (43). Inhalation studies with guinea pigs have been
difficult to interpret, since it has been impossible to determine whether the observed
effects were caused by the wood dust or by the mildew and lichens occurring
naturally in the wood (43).
Male rats (Sprague-Dawley) were given single intratracheal instillations of 1 ml
physiological saline solution containing either 15 mg respirable pinewood dust,
15 mg pinewood dust from which the cellulose had been removed with an organic
solvent, or 15 mg pure cellulose (54). The control group was given the saline solu-
tion alone. Histopathological examinations of lung tissue after one week and one
month revealed fibrosis-like changes in the rats exposed to the pinewood dust and the
cellulose, but no pathological changes were seen in the lungs of the rats given the
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cellulose-free extract. The authors attributed the results to the cellulose in the wood
dust.
Human data
Upper respiratory passages
Effects on the nose noted after exposure to wood dust are hypersecretion, congestion
and reduced mucociliary clearance (9).
Male employees (n=168) at furniture factories in Australia, who worked with the
hardwoods Tasmanian oak, teak and nyatoh (Palaquium sp., Payena sp.), as well as a
species of pine (Pinus radiata), were interviewed about respiratory symptoms. Their
average exposure to wood dust, measured as inhalable dust, was 3.7 mg/m3 (0.4-
24 mg/m3, 171 measurements). The carpenters reported more symptoms of eye, ear
and nose irritation than a control group (n=46) made up of plumbers, refrigeration
mechanics, electricians and general mechanical workshop staff. The authors did not
find a statistically significant correlation between the reported symptoms and the
measured amounts of wood dust the individual subjects were exposed to. Since it is
likely that the members of the control group were also exposed to irritating sub-
stances, the correlation between subjective symptoms and wood dust may have been
underestimated (47). Male carpenters in New Zealand (n=44) who worked with rimu
(Dacrydium cupressinum) reported more symptoms such as work-related coughs and
sniffles, nasal congestion and rhinitis, than a control group of office workers (n=38)
matched for age and smoking habits. The difference was statistically significant
(p <0.01). Measured concentrations of wood dust ranged from 1.0 to 25.4 mg/m3
(median 3.6 mg/m3), and 32% of the samples were above the exposure limit of
5 mg/m3. No relationship between severity of symptoms and wood dust concentra-
tions or length of employment is reported in this study (46).
In another study, eye irritation and chronic sniffles were significantly correlated
(p <0.05) to exposure to hardwood dust. No wood dust concentrations were reported
(17).
Symptoms such as rhinitis, nasal congestion, and irritation and itching in the nose
at the end of the workweek were more common among 39 woodworking teachers
exposed to total dust concentrations in the range 0.12 to 1.18 mg/m3 (respirable
fraction 0.02-0.21 mg/m3), mostly from pine, than in a control group (n=32) consis-
ting of other personnel at the school. The symptoms diminished during periods away
from work, and mucociliary clearance deteriorated during the week. The study
revealed no correlation and no dose-effect relationship between dust concentration
and nasal symptoms (64). In another Swedish study, 40 woodworking teachers were
screened for inflammatory markers in nasal lavage fluid, but no clear indications of
inflammation were found (65).
A case of allergic rhinitis and conjunctivitis was diagnosed in a goldsmith who had
been exposed to dust from spindle tree wood (Euónymus europaeus) (24).
Lower respiratory passages
Western red cedar (Thuja plicata). Vedal et al. (58) reported an 8% prevalence of
occupational asthma among 652 examined sawmill workers who handled Western
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red cedar (WRC). The criteria for the occupational asthma diagnosis were recurring
cough, wheezing, phlegm, breathing difficulty or tightness in the chest; that these
symptoms were not experienced before employment at the sawmill; and that they
improved during weekends or longer absences from work. Occupational asthma was
more common among those employed for 10 years or longer. Exposure levels for
334 workers were estimated from readings from 46 monitoring stations, 32 personal
monitors, occupational title and workplace. The prevalence of work-related eye
symptoms increased with exposure to total dust concentrations ≥2.0 mg/m3 (p=0.02).
After adjustment for smoking habits, height, age and ethnic background, the workers
exposed to dust concentrations ≥2.0 mg/m3 had significantly lower FVC and FEV1
values (p <0.05) than controls (440 male office workers).
Vedal et al. monitored bronchial hyperresponsiveness in 227 of these workers in a
longitudinal study stretching over three years (59). Bronchial hyperresponsiveness
was diagnosed by provocation with methacholine. Fifteen percent of the subjects had
a diagnosed non-specific bronchial hyperresponsiveness during the entire study
period, and 17% of the subjects either developed it or recovered from it during the
course of the study. The prevalence of IgE antibodies specific for plicatic acid was
higher among subjects with bronchial hyperresponsiveness during the entire three-
year period than among those who either did not have it or developed/recovered from
it during that time. This indicates that immunological sensitivity to plicatic acid is
associated with development of non-specific bronchial hyperresponsiveness upon
exposure to WRC.
Four sawmill workers who developed WRC asthma did not have non-specific
bronchial hyperresponsiveness before the occupational asthma was diagnosed – it
developed along with the asthma. According to the authors, this indicates that the
hyperresponsiveness is not a predisposing factor for the asthma. The criteria for the
asthma diagnoses were ≥15% reduction in FEV1 within 12 hours after the end of the
workday and a positive reaction to provocation with plicatic acid (5).
In an 11-year follow-up study of 243 non-asthmatic sawmill workers who handled
WRC, these workers were found to have a chronic decline of FEV1 and FVC that was
significant when compared to controls (140 office workers). Measurements of total
dust (n=916) were made with personal monitors on five occasions during the 11-year
period (1982 –1993). Cumulative exposure was estimated on the basis of employ-
ment history, and average exposures were calculated by dividing the cumulative
exposure by the duration of employment. The sawmill workers were divided into
three exposure groups – low, medium and high – with average exposures of 0.13,
0.30 and 0.60 mg/m3 respectively. During the study period, FVC and FEV1 in both
the high-exposure and medium-exposure groups declined significantly more than in
controls. There was also a significant dose-response relationship between exposure
and annual reduction of FVC. The authors present this as evidence that an average
exposure of about 0.3 mg/m3 to wood dust from Western red cedar for at least 11
years causes a reduction in lung function (45).
Eastern white cedar (Thuja occidentalis) also contains plicatic acid. Occupational
asthma was diagnosed in 7% (3) of 42 employees and former employees at a sawmill
56
handling this type of wood. The criterion for the diagnosis was a positive reaction to
provocation with plicatic acid. The three employees with asthma had worked at the
sawmill for an average of 13 months. Total dust values ranged from 0.9 to 12.2 mg/m3,
and 50% of the measurements showed concentrations exceeding 2 mg/m3 (40).
Redwood (Sequoia sempervirens) dust can also cause occupational asthma (8, 43).
At present it is impossible to determine an exposure limit for dust of either WRC or
redwood that will eliminate this risk (43). The elevated risk of asthma from exposure
to WRC dust is believed to be due to sensitization to plicatic acid (43).
There are also several case reports (see Table 2) of occupational asthma after
exposure to other types of wood dust, mostly from hardwoods and exotic woods but
also in some cases softwoods. Although sensitization to softwoods that do not
contain plicatic acid has not been reported (43), this type of dust is regarded as an
irritant. The underlying reason for its irritative effect, however, is unknown (43).
Other conifers. In a cross-sectional study (19), 103 sawmill workers exposed to
dust from spruce, pine and Douglas fir were examined for symptoms involving the
respiratory passages, and lung function was tested. The control group comprised 52
machinists who were not exposed to wood dust. The average exposures to wood dust,
expressed as inhalable dust, were 0.2-1.1 mg/m3 for the low-exposure job categories
and 1.3-6.3 mg/m3 for the high-exposure ones. Exposure to mildew was measured
with personal monitors, and ranged from 5000 to 33,000 cfu/m3 (cfu = colony-
forming units), which can be regarded as fairly low. The measured dust exposure for
the control group was 2.5 mg/m3. Their exposure to mildew was not measured. There
was no significant difference between the groups in either FEV1 or FVC. Subjects in
the high-exposure group reported work-related coughs, shortness of breath and
wheezing significantly more often than controls, and the authors regard these
symptoms as indications of bronchial hypersensitivity.
Workers (n=94) handling pine and spruce at a Canadian sawmill were tested with
spirometry (FEV1 and FVC) and given a questionnaire covering job history, smoking
habits etc. Each of them was given prick tests for wheat, rye, Alternaria, cat dander,
household dust and birch. The control group consisted of 165 oilfield workers from
the same geographical area, matched for age, height and smoking habits. FEV1 and
FVC% were significantly lower among the sawmill workers than in the control group,
which the authors regard as indicating an obstructive reduction in lung function. The
greatest difference between exposed subjects and controls was noted for smokers.
Symptoms in the form of breathing difficulty or wheezing were reported significantly
more often by the sawmill workers, with odds ratios (OR) of 2.83 (95% CI=1.47-
5.46) and 2.58 (95% CI=1.18-5.62) respectively. Workers who had been employed at
the sawmill for longer than three years had significantly higher odds ratios for
asthma-like symptoms (OR=3.67; 95% CI=1.00-13.5) and bronchitis (OR=2.14; 95%
CI=1.02-4.52). Air concentrations of wood dust with a particle size ≤10 µm were
measured with stationary monitors at five different places (average 1.35 mg/m3;
range 0.1-2.2 mg/m3). The authors attribute the symptoms reported by the sawmill
workers to wood dust, but also discuss the possibility that they may have been caused
by exposure to other substances in the air in a sawmill, such as terpenes (25).
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A group of 145 non-smoking African workers (77 men and 68 women) exposed to
dust from pine and from a type of fiberboard were tested with spirometry and
questioned about symptoms involving the eyes and upper respiratory passages (50).
Total dust was measured with stationary monitors in various parts of the workplaces
(average=3.82 mg/m3; SD=1.34 mg/m3). The controls were a group of non-smokers
(77 men and 75 women). The male carpenters had significantly lower FVC, FEF and
PEF values than the male controls. The proportion of men with an obstructive
reduction in lung function (FEV% <70%) was significantly higher in the exposed
group. The exposed workers also reported symptoms such as coughing and nasal
problems significantly more often than controls, and these symptoms were more
common among those who had been employed longer. The women did not have
lower lung function values – a result the authors explain by stating that they worked
in less dusty parts of the factory than the men, but they give no dust measurements
supporting this.
Workers (n=48) in four different sawmills where concentrations of pinewood dust
(measured as total dust) were between 0.1 and 1.1 mg/m3 showed a statistically
significant reduction in TLco during an 8-hour workday. Eye irritation also increased
significantly during the workday. Exposures to terpenes (registered by personal
monitors) ranged from 11 to 158 mg/m3, and a combined effect of wood dust and
terpenes can therefore not be ruled out (12). For employees (n=38) at four different
joinery shops, FEV1 at the beginning of the workday was lower than for unexposed
controls, and the FEV1/FVC quotient was also significantly lower than controls. This
is an indication of obstructive reduction in lung function, and it was attributed to
exposure to softwood dust (pine/spruce) and/or terpenes (11).
In a Swedish questionnaire survey of 130 woodworking teachers, they reported
more skin, eye, nose, throat and lung problems than a control group of other
employees (n=112) at the same schools, matched for age, sex and smoking habits
(OR=12.4; 95% CI=2.96-110.5). The problems were more pronounced when the
ventilation in the workshop was poor, when there were dust-spreading machines, and
when cleaning stirred up dust. The authors concluded that wood dust was the
probable reason for the reported health problems. Pine was the most frequently used
type of wood, but linden (Tilia), birch and alder, as well as plywood and particle
board, were also used fairly often. Exotic woods were seldom used. There were also
other substances, such as vapors from solvents, water-soluble glues and varnish,
which according to the authors may have contributed to the effect (66). No dust
measurements were made. In a follow-up study it was found that IgE-mediated
allergy was not the underlying reason for the symptoms reported by the teachers
(65).
Tropical and other hardwoods. Male carpenters in New Zealand (n=44), who
worked with rimu (Dacrydium cupressinum), were screened for occupational asthma.
They were given a questionnaire to fill in, and PEF was measured daily for 10
consecutive days (both workdays and weekend). The criteria for occupational asthma
were a history of work-related respiratory symptoms of suspected asthma type
(identified by the answers on the questionnaire) and a variation in PEF >15% for at
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least two days within the ten-day period. Five workers met these criteria for occupa-
tional asthma. Measured wood dust concentrations ranged from 1.0 to 25.4 mg/m3
(median 3.6 mg/m3), and 32% of the readings were above the exposure limit of
5 mg/m3. Measured formaldehyde levels in the workplaces ranged from 0.01 to
0.27 mg/m3 (46).
After adjustment for smoking habits, reduced lung function was more prevalent
(29.4%) among 109 sawmill workers exposed to dust from sheesham (Dalbergia
sissoo) and mango (Mangifera indica) than in a group of 88 controls with the same
socioeconomic and ethnic background (2.2%). The reductions in lung function were
mostly of the restrictive type. The FEV1/FVC quotient is not given, and no dust
concentrations are reported (48).
Goldsmith and Shy (17) studied workers exposed to hardwood dust during
carpentry. There was a correlation between PEF reduction during a workday and
work with hardwoods (p <0.03).
Persons exposed to hardwood dust during production of wood powder for incense
sticks were examined in a study in Taiwan. MMF, PEFR and FEF25% were signi-
ficantly lower in exposed workers than in controls, for both smokers and non-
smokers. Measured wood dust concentrations (total dust) ranged from 4.4 to
22.4 mg/m3, and the respirable fraction made up 2.4 to 50.2% (35).
Other studies. In a literature review by Halpin et al. (20), the authors concluded
that allergic alveolitis is a rare disease among sawmill workers except in Sweden,
where the prevalence of symptoms compatible with this diagnosis is 5 to 10 % in
groups with high exposure to wood dust. A case report from the UK describes a 34-
year-old sawmill worker who developed allergic alveolitis after 3.5 years of employ-
ment. The man worked mostly with spruce, but also Douglas fir and occasionally
other types of conifers. Immunological tests showed IgG antibodies for mildew and
wood dust extract. The authors attribute his allergic alveolitis to the mildew, but
suggest that the wood dust may have had a synergistic effect (20). In another study
by the same authors (19), 103 sawmill workers were tested for immunological
reaction to a number of mildew species that may occur in and around a sawmill. The
control group consisted of 52 machinists. All five of the persons who had symptoms
resembling allergic alveolitis had high IgG-binding to Trichoderma koningii.
Carosso et al. (3) measured FVC, FEV1, FEV% , TLco and Kco (the ratio between
TLco and alveolar volume) in a group of carpenters and a control group matched for
age, height, weight and smoking habits. The carpenters were divided into a healthy
exposed group (A1, n=55), an exposed group with chronic cough and dyspnea
(B1, n=15), a group with dyspnea during work and bronchial hyperresponsiveness
(B2, n=20), and a group not exposed to wood dust (C, n=53). The asthmatic group
(B2) had positive prick tests for wood extract significantly more often than the
others; FVC and FEV% were significantly higher in B1 than in the other groups;
FEV1 was significantly lower in B1 than in B2, and in B2 than in A1 or controls.
TLco and Kco showed significant differences between all groups (B1 <B2 <A1 <C).
There were significant negative correlations between FEV1, MEF50, TLco and Kco
and the duration of exposure to wood dust. There were no significant differences in
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alveolar volume between the groups. The authors concluded that exposure to wood
dust or other substances around work with wood can induce chronic obstructive lung
disease. They attributed the reduction in diffusion capacity to an alveolitis-like
allergic reaction. Neither the types of wood nor the amounts of wood dust the
subjects were exposed to are reported.
Cryptogenic fibrosing alveolitis is a rare lung disease: in the UK it affects about 20
adults per 100,000. In an epidemiological study of persons with this disease, the
patients or their survivors were sent a questionnaire by post. The study covered 218
patients and 569 controls matched for age, sex and town of residence. Follow-up
telephone interviews were made with 165 cases and 408 controls. All 165 cases and a
control for each patient were tested for serum IgE, rheumatoid factor and anti-nuclear
antibodies, and given prick tests for common allergens. After adjustment for smoking
habits, exposure to wood dust was identified as a risk factor (OR=1.71; 95%
CI=1.01-2.92). No support was found for an interaction between exposure to wood
dust and rheumatoid factor, anti-nuclear antibodies, positive prick test for allergens
or IgE concentration (27).
Skin
Handling wood or wood dust and skin contact with airborne wood dust can cause
both irritative and allergic contact eczema. Occupational eczema occurs among
lumberjacks, carpenters and others who work in forestry, furniture production and
cabinetry. Hand eczema has been reported among persons who do wood inlay with
exotic woods (22).
Many tropical tree species contain quinones, which are powerful contact allergens.
Allergic contact eczema can also be caused by terpenes and colophony from conifers.
Swedish hardwoods such as alder, ash, beech, birch and poplar contain several sub-
stances that occasionally cause cases of contact allergy. Dust from lichens on tree
trunks contains several allergenic acids that can cause contact allergy easily
misdiagnosed as allergy to wood dust (10, 44).
In a Swedish survey (42) of 84 male woodworking teachers that worked with
spruce, juniper, pine and birch, two of them had positive patch tests for pine, spruce
and colophony, and one also had a positive reaction to juniper. The authors
concluded that persons sensitized to colophony may develop contact eczema from
wood dust. The one-year prevalence for all types of hand eczema among the studied
teachers was 19%, whereas the reported prevalence among men in the general
population was 9%.
In a patch-test screening of woodworking teachers, it was found that 19% of them
(16/84) had a positive reaction to extract of jelutong (Dyera costulata). Half of these
reported skin symptoms that could be related to their exposure to that type of wood.
The extract was tested on guinea pigs, and the results indicated that jelutong contains
potent contact allergens (41).
Medical examinations of 479 workers in the furniture industry in Singapore, who
were exposed mostly to hardwoods, revealed occupation-related skin problems
(itching and irritation) in 3.8% of them (15).
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Mutagenicity
In vitro and in vivo
Beechwood dust dissolved in a polar solvent caused point mutations in bacteria and
single-strand DNA breaks in rat hepatocytes. Extract from spruce did not have these
effects (29).
Lung cells from human embryos were exposed to a pesticide-free methanol extract
(pH=3.0) of beech, oak or pine, either with or without metabolic activation (S9).
Dose-dependent chromosome breaks were caused by oak, and dose-dependent
chromatid breaks were caused by both beech and oak, without metabolic activation.
It was concluded that wood dust from beech and oak contains genotoxic substances,
but these substances have not been identified (63).
Beech extract in a polar solvent induced micronuclei in rat tissue in vivo (29). Two
intraperitoneal injections of an aqueous extract of birch dust, given on consecutive
days, induced micronuclei in the erythrocytes of mice. Heat-treating the extract
significantly reduced the formation of micronuclei (31).
Human data
The frequency of micronuclei in peripheral leucocytes was studied in 83 workers
exposed to birch dust. The group of workers with the highest average exposure
(1.6 mg/m3) had a significantly (p <0.01) higher frequency of micronuclei than the
control group (88 waiters/waitresses). The frequency of micronuclei did not increase
with the duration of employment, and was higher in non-smokers than in smokers
(31).
Carcinogenicity
Animal data
The IARC has concluded that there are insufficient data to allow determination of
whether there is a relationship between wood dust and cancer in animals (29).
In the British criteria document (43), which treats only exposure to softwood dust,
it was concluded that there were no reliable studies on whether this type of dust can
cause cancer in animals.
Human data
According to the IARC (29), wood dust can cause sinonasal adenocarcinoma. This
conclusion is based primarily on studies of exposure to hardwood dust. No corre-
lation has been found between exposure to wood dust and squamous cell carcinoma
in the nose or tumors in the throat, trachea, lungs, lymphatic or circulatory system,
stomach, large intestine or colon (29).
A correlation between exposure to wood dust and sinonasal adenocarcinoma has
been described for European workers exposed to wood dust, but case-control studies
from America have shown little or no increase in risk for adenocarcinoma. The
reason for the discrepancy is not known. The authors propose as possible explana-
tions that other types of wood are used, that the processing methods are different,
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that the dust exposure is different and/or that there are other substances in the air in
the European workplaces (2).
Since the IARC published its monograph on wood dust, further studies on cancer
and wood dust have been published:
In a Canadian case-control study of 23 cases of myeloma, 54 cases of Hodgkin’s
lymphoma, and 215 cases of non-Hodgkin’s lymphoma reported during a seven-year
period (1979-1985), no correlation was found between exposure to wood dust and
these forms of cancer. The exposure estimates were based on questionnaires and
personal interviews of both cancer cases and controls (14).
In a Finnish case-control study, exposure to wood dust was surveyed among 136
men with cancers in the lungs or upper respiratory passages. There were three
matched controls for each cancer case. For dust concentrations around 1 mg/m3 from
pine, spruce and birch, the study found no correlation to cancer in the lungs or upper
respiratory passages or to nasal adenocarcinomas. Exposure estimates were based on
workplace monitoring, workplace visits and personal interviews/questionnaires (32).
Similar results were reported in a recently published case-control study of 48 cases
of nasal cancer (types not given) and matched controls. Exposure estimates were
based on job titles and on interviews with cases and controls. The authors suggested
that the reasons no correlation was found were the relatively low exposure to wood
dust (<1 mg/m3) and the fact that the dust was almost entirely from softwoods (56).
In a Belgian case study of 386 cases of sinus cancer reported in 1978-1994, there
were 139 adenocarcinomas and 90 squamous cell carcinomas: 88 (63%) of the
adenoma cases had jobs involving work with wood, and 9 (10%) of the 90 patients
who had squamous cell carcinomas had been exposed to wood dust (57). The study
does not report whether this was hardwood or/and softwood dust.
In a pooled re-analysis of 12 case-control studies of nasal cancer made in 7 diffe-
rent countries, it was found that there was a high risk of adenocarcinoma (OR=13.5;
95% CI=9.0-20.0) especially among male woodworkers exposed to dust from hard-
woods. No dust concentrations are given. The workers were divided into three expo-
sure groups, with estimated exposures of <1 mg/m3, 1-5 mg/m3, and >5 mg/m3. For
each cancer case there was at least one unexposed control. The highest exposure
group included machine operaters in the wood processing industry, furniture makers
and carpenters. The risk was most pronounced among those exposed to the highest
concentrations of wood dust (OR=45.5; 95% CI=28.3-72.9), and it increased with
duration of exposure. There was also a tendency to elevated risk among women
(OR=2.5; 95% CI=0.5-12.3), but there were relatively few cases in the study. The
results revealed no elevation in risk of squamous cell carcinoma in the nose (6).
A re-analysis of five published cohort studies on cancer mortality among workers
exposed to wood dust revealed an elevated risk of cancer in the nose (types not
reported) and throat. The nasal cancer was correlated to exposure to hardwood dust.
Throat cancer was observed among furniture makers and workers exposed to dust
from plywood. A trend toward elevated risk of multiple myeloma after exposure to
wood dust was also found. The study did not find elevated risks for cancers in the
lungs, larynx, stomach or large intestine. The authors point out that the lack of
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exposure data and the lack of information on exposures to other substances such as
formaldehyde, solvents and pesticides/herbicides may have led to an underestimate
of the risks (7).
Leclerc et al. (33) made a case-control study among French workers whose nasal
cancer was diagnosed during the years 1986 –1988. Of 207 cases, 82 were adeno-
carcinomas. Of these, 80 had been exposed to hardwood dust or a mixture of hard-
wood and softwood dust.
In a study (18) in which two different methods were used to weigh together the
results of several epidemiological studies, it was found that workers exposed to wood
dust (carpenters, workers in furniture factories, and all wood-related occupations)
had an elevated risk of nasal adenocarcinoma. The risk was highest for the furniture
makers (RR 30 and 71, compared to 18 and 35 for carpenters). There was no increase
in the risk of squamous-cell carcinomas in the nose, however.
In a prospective register study made in the United States (52), an elevated risk of
lung cancer was found among persons who reported exposure to wood dust
(RR=1.17; 95% CI=1.04-1.31). In the study, consideration was given to smoking
habits. One difficulty in interpreting the results is that there was some correlation
between wood-dust exposure and exposure to asbestos. There was no observed
elevation in the risk of nasal cancer (one case; RR 1.05).
There is a case-control study exploring the relationship between lung cancer and
sensitivity to mutagens. Sensitivity was measured as chromatid breaks/lymphocytes
in cell cultures briefly treated with bleomycin. The cases (n=108) were Americans of
African or Mexican descent with newly diagnosed and untreated lung cancer.
Controls (n=264) were persons from the surrounding communities, matched for
ethnic background, age and sex. Information on exposure to wood dust was obtained
from interviews and based on job descriptions. Exposure to wood dust was asso-
ciated with an elevated risk of sensitivity to mutagens. No information is given on
the type of wood dust or the level or duration of exposure (62).
A recently published German study (61) explores combination effects between
malignant tumors in the nose and exposure to hardwood dust (beech and oak) and
substances present in wood dust, such as pigments, paints and the insecticides
lindane and pentachlorophenol (PCP). Genotoxic effects in the form of single-strand
DNA breaks were studied in rat hepatocytes in vitro. The extracts from oak and
beech caused single-strand DNA breaks, but so did PCP and lindane, 5 of 16
pigments, 2 of 11 paints, and 3 of 8 wood preservatives used in the German wood
processing industry. Examination of samples of human nasal tissue revealed a higher
fequency of dysplasias among subjects exposed to dust from beech and oak. Subjects
exposed to wood preservatives had nasal dysplasias only if they had been
simultaneously exposed to beech or oak dust. The effect was not statistically signi-
ficant, however (p >0.07). There were few cases. Most of the 147 cancer cases
classified as occupational disease since 1985 were workers in smaller companies,
and had been exposed to several other substances. The authors conclude from the
presented data that combined exposure to wood dust and other substances present in
the work environment causes nasal cancer.
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Teratogenicity
Animal and human data
No data were found.
Dose-response/dose-effect relationships
Studies which give a correlation between dust concentrations and symptoms are
presented in Table 3. Elevated occurrences of symptoms involving the upper and
lower respiratory tract, as well as effects on lung function, have been observed with
exposure to pinewood dust in the concentration range 0.1-6.3 mg/m3. Asthma and/or
reduction of lung function have been observed with exposure to WRC dust at
average concentrations of 0.3-6.0 mg/m3. Exposure to dust from eastern white cedar
in the range 0.9-12 mg/m3 caused occupational asthma in 3 of 42 workers. For dust
from aspen, a reduction of lung function was documented at an average respirable
content of 0.25 mg/m3. Exposure to dust from other hardwoods in concentrations of
0.4-24 mg/m3 has caused irritation in upper respiratory passages and declines in
MMF, PEFR and FEF25%.
Conclusions
The critical effect of occupational exposure to wood dust is irritation of eyes and
upper respiratory passages. Exposure to wood dust can cause sinonasal
adenocarcinoma. This conclusion is based primarily on studies of exposure to
hardwood dust.
Exposure to dust from Western red cedar (WRC) in the concentration range 0.3-
0.6 mg/m3 has caused asthma, chronic decline in lung function and irritation of eyes
and upper respiratory passages. Exposure to wood dust from spruce and pine in the
concentration range 0.1-6.3 mg/m3 causes irritation of eyes and upper respiratory
passages. One study indicates that long-term exposure to softwood dust at levels of
about 1 mg/m3 can affect lung function.
Exposure to hardwood dust causes acute irritation in eyes and upper respiratory
passages and may also reduce lung function. There are not enough data to allow
determination of the level at which these effects appear.
Skin exposure to wood dust can cause both allergic and non-allergic contact
eczema.
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Table 3. Dose-effect and dose-response relationships for effects on respiratory passages
from occupational exposure to wood dust, measured as mg/m3 total dust. (n.r. = not reported)
Average (range) Wood type Effects Ref.
0.3 (0.1-1.1) Pine Decline of TLco,
Eye irritation
12
n.r. (1.3-6.3) Spruce, pine Irritation in nose and eyes,
bronchial hyperresponse
19
1.35 (0.1-2.2) Spruce, pine Reduction of FEV1, FEV%
irritation in upper airways
25
3.82 (n.r.) Pine, fiberboard Reduction of FVC, PEF, FEF 50
0.131 (n.r.) WRC No reduction of FVC 45
0.301 (n.r.) WRC Reduction of FVC 45
0.611 (n.r.) WRC Reduction of FVC 45
0.46 (≤0.1-6.0) WRC Eye irritation, reduction of FEV1, FVC,
Asthma in 8% of 652 workers
58
23 (0.9-12) Eastern white cedar Asthma in 7% of 42 workers 40
0.272 (n.r.) Aspen Reduction of FEV1, FVC 23
3.62 (1.0-25.4) Rimu Coughs, sniffles, rhinitis,
nasal congestion
46
12.0 (4.4-22.4) Hardwoods Reduction of MMF, PEFR,
FEF25%
35
3.73 (0.4-24) Hardwoods Irritated eyes, ears, nose 47
0.57 (0.12-1.18) (n.r.) Nasal irritation 64
1
 = geometric mean for 11 years of exposure
2
 = respirable fraction
3
 = median value
66
References
1. Basomba A, Burches E, Almodovar A, Hemandez MD, deRojas DH. Occupational rhinitis and
asthma caused by inhalation of Balfourodendron riedelianum (Pau Marfim) wood dust. Allergy
1991;46:316-318.
2. Blot WJ, Chow W-H, McLaughlin JK. Wood dust and nasal cancer risk. J Occup Environ Med
1997;39:148-155.
3. Carosso A, Ruffino C, Bugiani M. Respiratory diseases in wood workers. Br J Ind Med
1987;44:53-56.
4. Cartier A, Chan H, Malo J-L, Pineau L, Tse KS, Chan-Yeung M. Occupational asthma caused by
eastern white cedar (Thuja occidentalis) with demonstration that plicatic acid is present in this
wood dust and is the causal agent. J Allergy Clin Immunol 1986:77:639-645.
5. Chan-Yeung M, Desjardins A. Bronchial hyperresponsiveness and level of exposure in
occupational asthma due to western red cedar (Thuja plicata). Am Rev Respir Dis
1992;146:1606-1609.
6. Demers PA, Kogevinas M, Boffetta P, Leclerc A, Luce D, Gérin M, Battista G, Belli S, Bolm-
Audorf U, Brinton LA, Colin D, Comba P, Hardell L, Hayes RB, Magnani C, Merler E, Morcet
JF, Preston-Martin S, Matos E, Rodella S, Vaughan TL, Zheng W, Vainio H. Wood dust and
sino-nasal cancer: Pooled reanalysis of twelve case-control studies. Am J Ind Med 1995;28:151-
166.
7. Demers PA, Boffetta P, Kogevinas M, Blair A, Miller BA, Robinson CF, Roscoe RJ, Winter PD,
Colin D, Matos E, Vainio H. Pooled reanalysis of cancer mortality among five cohorts of
workers in wood-related industries. Scand J Work Environ Health 1995;21:179-190.
8. Demers PA, Teschke K, Kennedy SM. What to do about softwood? A review of respiratory effects
and recommendations regarding exposure limits. Am J Ind Med 1997;31:385-398.
9. Donback-Jensen L. Nordic Expert Group for Documentation of Occupational Exposure Limits 77.
Trästøv. Arbete och Hälsa 1987;36:1-57. (Summary in English)
10. Ducombs G, Schmidt RJ. Woods. In: Rycroft R, Menné T, Frosch P, eds. Textbook of Contact
Dermatitis. Berlin: Springer verlag, 1995:613-617.
11. Eriksson K, Levin J-O, Sandström T, Lindström-Espeling K, Lindén G, Stjernberg N. Terpene
exposure and respiratory effects among workers in Swedish joinery shops. Scand J Work
Environ Health 1997;23:114-120.
12. Eriksson K, Stjernberg N, Levin J-O, Hammarström U, Ledin M-C. Terpene exposure and
respiratory effects among sawmill workers. Scand J Work Environ Health 1996;22:182-190.
13. Fernández-Rivas M, Pérez-Carral C, Senent CJ. Occupational asthma and rhinitis caused by ash
(Fraxinus excelsior) wood dust. Allergy 1997;52:196-199.
14. Fritschi L, Siemiatycki J. Lymphoma, myeloma and occupation: Results of a case-control study.
Int J Cancer 1996;67:498-503.
15. Gan SL, Goh CL, Lee CS, Hui KH. Occupational dermatosis among sanders in the furniture
industry. Contact Dermatitis 1987;17:237-240.
16. Godni’c-Cvar J, Gomzi M. Case report of occupational asthma due to palisander wood dust and
bronchoprovocation challenge by inhalation of pure wood dust from a capsule. Am J Ind Med
1990;18:541-545.
17. Goldsmith DF, Shy CM. Respiratory health effects from occupational exposure to wood dust.
Scand J Work Environ Health 1988;14:1-15.
18. Gordon I, Boffetta P, Demers PA. A case study comparing a meta-analysis and a pooled analysis
of studies of sinonasal cancer among wood workers. Epidemiology 1998;9:518-524.
19. Halpin DMG, Graneek BJ, Lacey J, Nieuwenhuijsen MJ, Williamson PAM, Venables KM,
Newman Taylor AJ. Respiratory symptoms, immunological responses and aeroallergen
concentrations at a sawmill. Occup Environ Med 1994;51:165-172.
67
20. Halpin DMG, Graneek BJ, Turner-Warwick M, Newman Taylor AJ. Extrinsic allergic alveolitis
and asthma in a sawmill worker: case report and a review of the literature. Occup Environ Med
1994;51:160-164.
21. Hamill A, Ingle J, Searle S, Williams K. Levels of exposure to wood dust. Ann Occup Hyg
1991;35:397-403.
22. Hausen BM. Contact allergy to woods. Clin Dermatol 1986;4:65-76.
23. Herbert FA, Hessel PA, Melenka LS, Yoshida K, Nakaza M. Respiratory consequences of
exposure to wood dust and formaldehyde of workers manufacturing oriented strand board. Arch
Environ Health 1994;49:465-470.
24. Herold DA, Wahl R, Maasch HJ, Hausen BM, Kunkel G. Occupational wood-dust sensitivity from
Euonymus europaeus (spindle tree) and investigation of cross reactivity between E.e. wood and
Artemisia vulgaris pollen (mugwort). Allergy 1991;46:186-190.
25. Hessel PA, Herbert FA, Melenka LS, Yoshida K, Michaelchuk D, Nakaza M. Lung health in
sawmill workers exposed to pine and spruce. Chest 1995;108:642-646.
26. Hinojosa M, Losada E, Moneo I, Dominguez J, Carrillo T, Sanchez-Cano M. Occupational asthma
caused by African maple (Obeche) and Ramin: evidence of cross reactivity between these two
woods. Clin Allergy 1986;16:145-153.
27. Hubbarb R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood
dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996;347:284-289.
28. Innocenti A, Romeo R, Mariano A. Asthma and systemic toxic reaction due to cabreuva
(Myrocarpus fastigiatus, Fr. All) wood dust. Med Lav 1991;82:446-450.
29. IARC. Wood dust and formaldehyde. IARC Monographs on the Evaluation of Carcinogenic Risks
to Humans, 1995;62:35-215.
30. Jeebhay MF, Prescott R, Potter PC, Ehrlich RI. Occupational asthma caused by imubia wood dust.
J Allergy Clin Immunol 1996;97:1025-1027.
31 Jiang Z-C, Su Y-L, Deng Y-F, Sun W, Liu W-C, Wei D-M. The chromosomal effect of birchen
dust as determined by the micronucleus test. Biomed Environ Sci 1997;10:396-401.
32. Kauppinen TP, Partanen TJ, Hernberg SG, Nickels JI, Luukkonen RA, Hakulinen TR, Pukkala EI.
Chemical exposures and respiratory cancer among Finnish woodworkers. Br J Ind Med
1993;50:143-148.
33. Leclerc A, Cortes M, Gérin M, Luce D, Brugère J. Sinonasal cancer and wood dust exposure:
Results from a case-control study. Am J Epidemiol 1994;140:340-349.
34. Lidblom A. Exposition för damm i svensk träbearbetande industri 1994/1995. National Board of
Occupational Safety and Health, report 1997:1, Stockholm, 1997. (In Swedish)
35. Liou S-H, Cheng S-Y, Lai F-M, Yang J-L. Respiratory symptoms and pulmonary function in mill
workers exposed to wood dust. Am J Ind Med 1996;30:293-299.
36. Maestrelli P, Marcer G, Vecchio LD. Occupational asthma due to ebony wood (Diospyros
crassiflora) dust. Ann Allergy 1987;59:347-349.
37. Malo J-L, Cartier A. Occupational asthma caused by exposure to ash wood dust. Eur Respir J
1989;2:385-387.
38. Malo J-L, Cartier A, Boulet L-P. Occupational asthma in sawmills of eastern Canada and United
States. J Allergy Clin Immunol 1986;78:392-398.
39. Malo J-L, Cartier A, Desjardins A, Weyer RV, Vandenplas O. Occupational asthma caused by oak
wood dust. Chest 1995;108:856-858.
40. Malo J-L, Cartier A, L’archeveque J, Trudeau C, Courteau J-P, Bherer L. Prevalence of
occupational asthma among workers exposed to eastern white cedar. Am J Respir Crit Care Med
1994;150:1697-1701.
41. Meding B, Karlberg A-T, Åhman M. Wood dust fom jelutong (Dyera costulata) causes contact
allergy. Contact Dermatitis 1996;34:349-353.
68
42. Meding B, Åhman M, Karlberg A-T. Skin symptoms and contact allergy in woodwork teachers.
Contact Dermatitis 1996,34:185-190.
43. Minty C, Saleem A, Wagg R, Gillies C. Softwood dust. Criteria document for an occupational
exposure limit. Sheffield: HSE, 1996.
44. Mitchell J. Woods. In: Cronin E, ed. Contact Dermatitis. Edinburgh: Churchill Livingstone,
1980:548-574.
45. Noertjojo HK, Dimich-Ward H, Peelen S, Dittrick M, Kennedy SM, Chan-Yeung M. Western red
cedar dust exposure and lung function: A dose-response relationship. Am J Respir Crit Care Med
1996;154:968-973.
46. Norrish AE, Beasley R, Hodgkinson EJ, Pearce N. A study of New Zealand wood workers:
exposure to wood dust, respiratory symptoms, and suspected cases of occupational asthma. NZ
Med J 1992;105:185-187.
47. Pisaniello DL, Connell KE, Muriale L. Wood dust exposure during furniture manufacture – results
from an Australian survey and considerations for the threshold limit value development. Am Ind
Hyg Assoc J 1991;52:485-492.
48. Rastogi SK, Gupta BN, Husain T, Mathur N. Respiratory health effects from occupational
exposure to wood dust in sawmills. Am Ind Hyg Assoc J 1989;50:574-578.
49. Scheeper B, Kromhout H, Boleij JSM. Wood-dust exposure during wood-working processes. Ann
Occup Hyg 1995;39:141-154.
50. Shamissain MH. Pulmonary function and symptoms in workers exposed to wood dust. Thorax
1992;47:84-87.
51. Spiewak R, Bozek A, Maslowski T, Brewezynski PZ. Occupational asthma due to wood dust
exposure (ash, oak, beech and pine) – a case study. Annals of Agriculture and Environmental
Medicine 1994;1:73-76.
52. Stellman SD, Demers PA, Colin D, Boffetta P. Cancer mortality and wood dust exposure among
participants in the American Cancer Society Cancer Prevention Study – II (CPS-II). Am J Ind
Med 1998;34:229-237.
53. Swedish Standard SS-EN 481. Arbetsplatsluft – Partikelstorleksfraktioner för mätning av
luftburna partiklar. Swedish Institute for Standards – Swedish General Standards Institution
(SIS-STG), 1993. (In Swedish)
54. Tátrai E, Adamis Z, Böhm U, Merétey K, Ungváry G. Role of cellulose in wood dust induced
fibrosing alveo-bronchiolitis in rat. J Appl Toxicol 1995;15:45-48.
55. Teschke K, Hertzman C, Morrison B. Level and distribution of employee exposures to total and
respirable wood dust in two Canadian sawmills. Am Ind Hyg Assoc J 1994;55:245-250.
56. Teschke K, Morgan MS, Checkoway H, Franklin G, Spinelli JJ, van Belle G, Weiss NS.
Surveillance of nasal and bladder cancer to locate sources of exposure to occupational
carcinogens. Occup Environ Med 1997;54:443-451.
57. van den Oever R. Occupational exposure to dust and sinonasal cancer. An analysis of 386 cases
reported to the N.C.C.S.F. cancer registry. Acta Otorhinolaryngol Belg 1996;50:19-24.
58. Vedal S, Chan-Yeung M, Enarson D, Fera T, Maclean L, Tse KS, Langille R. Symptoms and
pulmonary function in western red cedar workers related to duration of employment and dust
exposure. Arch Environ Health 1986;41:179-183.
59. Vedal S, Enarson DA, Chan H, Ochino J, Tse KS, Chan-Yeung M. A longitudinal study of the
occurrence of bronchial hyperresponsiveness in western red cedar workers. Am Rev Respir Dis
1988;137:651-655.
60. Vinzents P, Laursen B. A national cross-sectional study of the working environment in the Danish
wood and furniture industry – air pollution and noise. Ann Occup Hyg 1993;37:25-34.
61. Wolf J, Schmezer P, Fengel D, Schroeder H-G, Scheithauer H, Woeste P. The role of combination
effects on the etiology of malignant nasal tumours in the wood-working industry. Acta
Otolaryngol Suppl (Stockh) 1998;535:1-16.
69
62. Wu X, Delclos GL, Annegers JF, Bondy ML, Honn SE, Henry B, Hsu TC, Spitz MR. A case-
control study of wood dust exposure, mutagen sensitivity, and lung cancer risk. Cancer
Epidemiol Biomarkers Prev 1995;4:583-588.
63. Zhou ZC, Norpoth KH, Nelson E. Genotoxicity of wood dust in a human embryonic lung cell line.
Arch Toxicol 1995;70:57-60.
64. Åhman M, Holmström M, Cynkier I, Söderman E. Work related impairment of nasal function in
Swedish woodwork teachers. Occup Environ Med 1996;53:112-117.
65. Åhman M, Holmström M, Ingelman-Sundberg H. Inflammatory markers in nasal lavage fluid
from industrial art teachers. Am J Ind Med 1995;28:541-550.
66. Åhman M, Söderman E, Cynkier I, Kolmodin-Hedman B. Work-related respiratory problems in
industrial arts teachers. Int Arch Occup Environ Health 1995;67:111-118.
70
Appendix 1. Abbreviations used in the text
Lung function
FVC Forced Vital Capacity
FEV1 Forced expiratory volume in one second
FEV% FEV expressed in % of FVC
FEF Forced expiratory flow
PEF Peak expiratory flow
MMF Flow between 25% and 75% of exhaled FVC
FEF25% Forced expiratory flow at 25% of FVC
Other
CI confidence interval
GM geometric mean
OR odds ratio
PCP pentachlorophenol
WRC Western red cedar
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Appendix 2. Scientific and common names for most of the softwoods and
hardwoods mentioned in this document
Genus/Species Common name
Softwoods
Abies fir
Abies balsamea Balsam fir
Chamæcyparis
Chamæcyparis thyoides
cedar
common white cedar
Cupressus cypress
Juniperus juniper
Larix larch
Picea
Picea abies
spruce
spruce
Picea mariana spruce
Pinus banksiana Jack pine
Pinus radiata pine
Pinus sylvestris Scotch pine/Norway pine
Pseudotsuga menziesii Douglas fir/Oregon pine
Sequoia sempervirens redwood
Thuja occidentalis eastern white cedar
Thuja plicata western red cedar
Tsuga hemlock
Hardwoods
Alnus alder
Balfourodendron riedelianum Pau Marfim
Betula birch
Chlorophora exelsa African teak (iroko)
Dacrydium cupressinum rimu/imou pine
Dalbergia nigra Brazilian rosewood
Dalbergia sissoo Sheesham/rosewood
Diospyros crassiflora ebony
Dyera costulata jelutong
Eucalyptus delegatensis,
Eucalyptus regnans,
Eucalyptus obliqua
Tasmanian oak
Euónymus europaéus spindle tree
Fagus beech
Fraxinus ash
Jacaranda (south america) palisander /rosewood
Juglans walnut
Khaya African mahogany
Mangifera indica mango
Myocarpus fastigiatus cabreuva
Palaquium spp nyatoh
Phoebe porosa Brazilian walnut
Populus aspen
Prunus cherry
Quercus oak
Meliaceae1 mahogany
Tectona grandis teak
Tilia linden/lime /basswood
Triplochiton scleroxylon Abachi /Africa maple /obeche
1Name of family
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Consensus Report for Sodium Hydroxide
August 24, 2000
Chemical and physical data. Occurrence
CAS No.: 1310-73-2
Synonyms: caustic soda, sodium hydrate, lye
Formula: NaOH
Molecular weight: 40.01
Boiling point: 1390°C
Melting point: 318.4°C
Vapor pressure (20°C): -
Solubility in water: 420 g/l at 0°C, 3470 g/l at 100°C
Sodium hydroxide is a white, hygroscopic substance that usually occurs in the form
of pellets, flakes, sticks or clumps, or as a 45 to 75% solution in water. Sodium
hydroxide is a strong base: a 0.1 M solution has a pH of 13. Sodium hydroxide
dissolves in water, generating heat which may cause steam.
Sodium hydroxide is an extremely common industrial chemical. It is used in the
manufacture of rayon and other textiles, soap, paper, aluminum, petroleum products,
chemicals and paints, in batteries, in developing photographic film and for cleaning
metals (1).
Uptake, biotransformation, excretion
Sodium hydroxide reacts with carbon dioxide to form sodium bicarbonate and
sodium carbonate. Sodium hydroxide is completely ionized in water. Sodium ions
are essential to human life, and are the most abundant cation in extracellular fluid.
Isotope-labeled sodium can be detected in human blood immediately after
intramuscular injection or application to intact skin, and within 3 minutes after oral
intake. The biological half time for sodium in humans was measured after injection
of isotope-labeled sodium: three excretion phases were observed, with half times of
8.5 days (49% of the dose), 13.5 days (51%) and 460 days (0.4%) (13).
Toxic effects
Human data
Sodium hydroxide's corrosive effects on skin are well documented (26). Malten and
Spruit (21) report damage to intact skin from 1 hour of exposure to as little as a 0.03
M (0.12%) solution under occlusion. The EU has developed a system for classifying
chemicals according to their skin irritation potential: according to this system a 0.5%
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sodium hydroxide solution applied under occlusion for 1 hour is classified as
irritating. After 1 hour the substance was classified as strongly irritating by half the
volunteers in the test (14). In an in vitro test using skin cultivated from human
keratinocytes (malpighian cells) to study corrosive substances (29), 2.4 minutes of
exposure to a 10% solution of sodium hydroxide reduced viability to 50%. In a 1%
solution 72% of the cells survived for 3 minutes.
Hughes concluded that the degree of damage from eye contact with an alkali
solution is dependent on the concentration, exposure time and penetration rate (18).
There are some case reports describing eye damage caused by alkali. Most of the
occupational injuries are the results of splashes. Alkali burns occur primarily in the
construction, chemical and manufacturing industries (19).
Sodium hydroxide reacts rapidly with carbon dioxide, forming carbonate, which
makes air analyses uncertain. According to Patty's Industrial Hygiene and
Toxicology (30), an air concentration of 250 mg/m3 is potentially lethal, but no
reference is given for this information. There are a few studies which describe
damage to the respiratory passages from exposure to aerosols of products containing
sodium hydroxide (16, 25, 32).
There is a study of 291 workers who had been exposed to sodium hydroxide dust
for from 1 to 30 years. Time-weighted average exposures were calculated from
monitoring data and subjective symptoms, and ranged from 0.5 to 2.0 mg/m3,
depending on the workplace. Subjective symptoms of irritation (not further
described) were reported in the areas with the highest average air levels, and the
measured exposure levels (19 monitoring occasions) ranged from 0 up to 6.7 mg/m3.
No significant increase in mortality related to exposure time or exposure levels was
found in comparisons with national averages. A review of medical records revealed
that medical treatment had been sought for irritation of skin, eyes and respiratory
passages after episodes of acute exposure. No exposure levels were reported (27).
A group of 14 volunteers, all men with mild asthma, inhaled via the mouth
alkaline aerosols in concentrations ranging from 4 to 127 mg/m3 for 20 minutes. The
aerosol was formed by the inflation of automobile air bags: it had a pH in the range
9.8 to 10.3 (no information is given on how this was measured) and consisted mostly
of sodium carbonate, sodium bicarbonate and a small amount of sodium hydroxide.
No further information on the exposure levels for sodium hydroxide are given. Lung
function tests, FEV1, and specific airway resistance revealed no statistically
significant changes. Some subjective symptoms – breathlessness, a burning sensation
in the throat and chest, cough reflex, chest tightness, etc. – were reported at the
exposure levels above 80 mg/m3 (12).
It is possible that the eyes are more sensitive than the lungs to aerosols of sodium
hydroxide. When sodium hydroxide particles enter the respiratory passages they are
rapidly transformed to less alkaline carbonate due to the presence of moisture and
carbon dioxide. Particles entering the eye, however, can cause locally high
concentrations on the eye's surface (9).
There are numerous case reports of accidents and suicide attempts with sodium
hydroxide (17), usually involving oral intake.
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Animal data
The LD50 for intraperitoneal injection to mice is 40 mg/kg. The LD50 for oral
administration to rabbits is 500 mg/kg (31).
The skin-damaging effects of sodium hydroxide have been studied in the
laboratory with rats and rabbits. A 4-hour exposure to a 2% solution of sodium
hydroxide caused chemical burns on rabbit skin (33), whereas a 1% solution caused
no damage. Bucher et al. (6) tested different concentrations of sodium hydroxide on
mouse skin. Two hours of exposure to solutions of 0.5 and 2.5% caused severe
irritation, and irritation from a 7.5% solution was judged to be extremely severe. A
cat was used to study the effects of sodium hydroxide on the esophagus (2). The cat
was anesthetized and the esophagus was opened. An 8% solution was applied for 30
seconds and then carefully rinsed off. After 2 hours there was severe reddening and
fluid formation at the site of the application, and underlying muscles were also
damaged.
Rabbits were used in a study of eye damage from sodium hydroxide (15). No
damage resulted from application of a 0.5% solution in the following volumes:
0.003, 0.01, 0.03 and 0.1 ml. However, 0.003 ml of a 10% solution caused irritation.
The rabbits had recovered after 7 days. Larger volumes – 0.01, 0.03, and 0.1 ml – of
the 10% solution produced severe eye damage. In another study (3), 0.1 ml of a 1%
or 10% sodium hydroxide solution was tested in rabbit eyes. The 1% solution caused
irritation, but the damage healed. The 10% solution caused severe irritation which
had still not healed after 21 days of observation. No irritation resulted from 0.1 ml of
a 1% solution applied to the eye of a monkey (7), but in rabbits the treatment resulted
in more severe damage. The cornea became opalescent, and took 14 days to heal.
Zwicker et al. (34) studied the effects of an aerosol mixture of sodium hydroxide,
sodium hydrogen carbonate, sodium bicarbonate and sodium carbonate on juvenile
and adult rats. The animals were exposed for 2 hours to 65 (nose only) or 250-3200
(whole-body) mg/m3 of an aerosol consisting mostly of sodium carbonate. For one of
the exposures all carbon dioxide was removed from the air. Even so, sodium
hydroxide entering the exposure chamber was rapidly transformed to carbonate by
the carbon dioxide in the air exhaled by the animals. The dose which had an effect on
50% of the exposed animals (ED50) was determined. The effect, which was identified
by histological examination, was acute laryngitis. No other damage could be found.
The ED50 for adult animals was 510 mg/m3 and for juveniles 489 mg/m3. Juveniles
developed more severe laryngitis than adult animals exposed to the same air
concentration.
Carcinogenicity
Human data
In a few case reports, carcinoma of the esophagus has been connected to previous
injury by lye (4, 5, 20, 28). This is probably due to the tissue damage and ulceration
resulting from exposure to a strong alkali rather than to any carcinogenic activity of
sodium hydroxide (22).
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Teratogenicity
Animal data
Two µl of 0.001 M sodium hydroxide was added to the amniotic fluid of mice after
13 days of gestation (11). Mortality and the occurrence of cleft palate were
registered. The treatment had no teratogenic effect, but caused high fetal mortality.
Mutagenicity
The chromosome-damaging effects of alkali were tested on hamster ovarian cells in
vitro. In sodium hydroxide solutions without metabolic activation (S9 mix) there was
no chromosome damage in the pH range 7.4 to 10.6 (24). A few chromosome
aberrations were observed with the addition of S9 mix at pH 10.6 (16 mM sodium
hydroxide). The frequency of aberrations increased with the amount of S9 mix
added. The proposed explanation for this result was that chromosome-breaking
products were formed by the breakdown of the S9 at high pH (24). Sodium
hydroxide did not increase the transformation of Syrian hamster cells by the
adenovirus SA7 (8). Genotoxic activity was assessed in Ames tests and in a DNA
repair test using several strains of S. typhimurium and E. coli. It was concluded that
sodium hydroxide was non-mutagenic (10). Several other strains of E. coli were used
in another study (23) in which no mutagenic activity was observed.
Dose-effect/dose-response relationships
There are no data from which to determine a dose-effect or dose-response
relationship for occupational exposure to sodium hydroxide. Sodium hydroxide
solutions are extremely corrosive. One hour of exposure to a 0.12% solution (under
occlusion) was irritating to the skin of human subjects. In eye irritation studies with
rabbits, 0.1 ml of a 0.5% solution dropped into the eye caused no irritation, whereas
0.003 ml of a 10% solution produced reversible damage and 0.01 ml of the same
10% solution caused severe damage.
Conclusions
There are no data from which to determine a critical effect of occupational exposure
to sodium hydroxide. However, because of its extremely high pH, the critical effect
is judged to be irritation of eyes, respiratory passages and skin.
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Summary
Montelius J (ed). Scientific Basis for Swedish Occupational Standards. XXI.
Arbete och Hälsa 2000:22, pp 1-85. National Institute for Working Life, Solna.
Critical review and evaluation of those scientific data which are relevant as a background
for discussion of Swedish occupational exposure limits. This volume consists of the
consensus reports given by the Criteria Group at the Swedish National Institute for
Working Life from July, 1999 through August, 2000.
Key Words: Amyl acetate, Antimony, Chromium, Chromium trioxide, Occupational
Exposure Limit (OEL), Pentyl acetate, Potassium dichromate, Potassium
hydroxide, Risk assessment, Scientific Basis, Sodium hydroxide,
Toxicology, Wood dust, Zinc chromate.
Sammanfattning
Montelius J (ed). Vetenskapligt underlag för hygieniska gränsvärden. XXI. Arbete och
Hälsa 2000:22, s 1-85. Arbetslivsinstitutet, Solna.
Sammanställningar baserade på kritisk genomgång och värdering av de vetenskapliga
fakta, vilka är relevanta som underlag för fastställande av hygieniskt gränsvärde.
Volymen omfattar de underlag som avgivits från Kriteriegruppen för hygieniska
gränsvärden under perioden juli 1999 - augusti 2000.
Nyckelord: Amylacetat, Antimon, Hygieniskt gränsvärde, Kaliumdikromat,
Kaliumhydroxid, Krom, Kromtrioxid, Natriumhydroxid, Pentylacetat, Risk
värdering, Toxikologi, Trädamm, Vetenskapligt underlag, Zinkkromat.
En svensk version av dessa vetenskapliga underlag finns publicerad i Arbete och Hälsa
2000:21.
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APPENDIX
Consensus reports in this and previous volumes
Substance Consensus date Volume in Arbete
och Hälsa (No.)
Acetaldehyde February 17, 1987 1987:39 (VIII)
Acetamide December 11, 1991 1992:47 (XIII)
Acetic acid June15, 1988 1988:32 (IX)
Acetone October 20, 1987 1988:32 (IX)
Acetonitrile September 12, 1989 1991:8 (XI)
Acrylamide April 17, 1991 1992:6 (XII)
Acrylates December 9, 1984 1985:32 (VI)
Acrylonitrile April 28, 1987 1987:39 (VIII)
Aliphatic amines August 25, 1982 1983:36 (IV)
Aliphatic hydrocarbons, C10-C15 June 1, 1983 1983:36 (IV)
Aliphatic monoketons September 5, 1990 1992:6 (XII)
Allyl alcohol September 9, 1986 1987:39 (VIII)
Allylamine August 25, 1982 1983:36 (IV)
Allyl chloride June 6, 1989 1989:32 (X)
Aluminum April 21, 1982 1982:24 (III)
revised September 14, 1994 1995:19 (XVI)
p-Aminoazobenzene February 29, 1980 1981:21 (I)
Ammonia April 28, 1987 1987:39 (VIII)
Amylacetate March 23, 1983 1983:36 (IV)
revised June 14, 2000 2000:22 (XXI)
Aniline October 26, 1988 1989:32 (X)
Anthraquinone November 26,1987 1988:32 (IX)
Antimony + compounds December 8, 1999 2000:22 (XXI)
Arsenic, inorganic December 9, 1980 1982:9 (II)
revised February 15, 1984 1984:44 (V)
Arsine October 20, 1987 1988:32 (IX)
Asbestos October 21, 1981 1982:24 (III)
Barium June 16, 1987 1987:39 (VIII)
revised January 26, 1994 1994:30 (XV)
Benzene March 4, 1981 1982:9 (II)
revised February 24, 1988 1988:32 (IX)
Benzoyl peroxide February 13, 1985 1985:32 (VI)
Beryllium April 25, 1984 1984:44 (V)
Borax October 6, 1982 1983:36 (IV)
Boric acid October 6, 1982 1983:36 (IV)
Boron Nitride January 27 1993 1993:37 (XIV)
Butadiene October 23, 1985 1986:35 (VII)
1-Butanol June 17, 1981 1982:24 (III)
Butanols June 6, 1984 1984:44 (V)
Butyl acetate June 6, 1984 1984:44 (V)
Butyl acetates February 11, 1998 1998:25 (XIX)
Butylamine August 25, 1982 1983:36 (IV)
Butyl glycol October 6, 1982 1983:36 (IV)
Cadmium January 18, 1980 1981:21 (I)
revised February 15, 1984 1984:44 (V)
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revised May 13, 1992 1992:47 (XIII)
Calcium hydroxide February 24, 1999 1999:26 (XX)
Calcium nitride January 27, 1993 1993:37 (XIV)
Calcium oxide February 24, 1999 1999:26 (XX)
Caprolactam October 31, 1989 1991:8 (XI)
Carbon monoxide December 9, 1981 1982:24 (III)
Cathecol September 4, 1991 1992:47 (XIII)
Chlorine December 9, 1980 1982:9 (II)
Chlorine dioxide December 9, 1980 1982:9 (II)
o-Chlorobenzylidene malononitrile June 1, 1994 1994:30 (XV)
Chlorocresol December 12, 1990 1992:6 (XII)
Chlorodifluoromethane June 2, 1982 1982: 24 (III)
Chlorophenols September 4, 1985 1986:35 (VII)
Chloroprene April 16, 1986 1986:35 (VII)
Chromium December 14, 1979 1981:21 (I)
revised May 26, 1993 1993:37 (XIV)
revised May 24, 2000 2000:22 (XXI)
Chromium trioxide May 24, 2000 2000:22 (XXI)
Coal dust September 9, 1986 1987:39 (VIII)
Cobalt October 27, 1982 1983:36 (IV)
Copper October 21, 1981 1982:24 (III)
Cotton dust February14, 1986 1986:35 (VII)
Creosote October 26, 1988 1989:32 (X)
Cresols February 11, 1998 1998:25 (XIX)
Cumene June 2, 1982 1982:24 (III)
Cyanamid September 30, 1998 1999:26 (XX)
Cyanoacrylates March 5, 1997 1997:25 (XVIII)
Cycloalkanes, C5-C15 April 25, 1984 1984:44 (V)
Cyclohexanone March 10, 1982 1982:24 (III)
revised February 24 1999 1999:26 (XX)
Cyclohexanone peroxide February 13, 1985 1985:32 (VI)
Cyclohexylamine February 7, 1990 1991:8 (XI)
Desflurane May 27, 1998 1998:25 (XIX)
Diacetone alcohol December 14, 1988 1989:32 (X)
Dichlorobenzenes February 11, 1998 1998:25 (XIX)
1,2-Dibromo-3-chloropropane May 30, 1979 1981:21 (I)
Dichlorodifluoromethane June 2, 1982 1982:24 (III)
1,2-Dichloroethane February 29, 1980 1981:21 (I)
Dichloromethane February 29, 1980 1981:21 (I)
Dicumyl peroxide February 13, 1985 1985:32 (VI)
Dicyclopentadiene March 23, 1994 1994:30 (XV)
Diethanolamine September 4, 1991 1992:47 (XIII)
Diethylamine August 25, 1982 1983:36 (IV)
2-Diethylaminoethanol January 25, 1995 1995:19 (XVI)
Diethylene glycol September 16, 1992 1993:37 (XIV)
Diethyleneglycol ethylether + acetate December 11, 1996 1997:25 (XVIII)
Diethyleneglycol methylether + acetate March 13, 1996 1996:25 (XVII)
Diethyleneglycol monobutylether January 25, 1995 1995:19 (XVI)
Diethylenetriamine August 25, 1982 1983:36 (IV)
revised January 25, 1995 1995:19 (XVI)
Diisocyanates April 8, 1981 1982:9 (II)
revised April 27, 1988 1988:32 (IX)
Diisopropylamine February 7, 1990 1991:8 (XI)
N,N-Dimethylacetamide March 23, 1994 1994:30 (XV)
Dimethyl adipate December 9, 1998 1999:26 (XX)
Dimethylamine December 10, 1997 1998:25 (XIX)
N,N-Dimethylaniline December 12, 1989 1991:8 (XI)
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Dimethyldisulfide September 9, 1986 1987:39 (VIII)
Dimethylether September 14, 1994 1995:19 (XVI)
Dimethylethylamine June 12, 1991 1992:6 (XII)
Dimethylformamide March 23, 1983 1983:36 (IV)
Dimethyl glutarate December 9, 1998 1999:26 (XX)
Dimethylhydrazine January 27, 1993 1993:37 (XIV)
Dimethyl succinate December 9, 1998 1999:26 (XX)
Dimethylsulfide September 9, 1986 1987:39 (VIII)
Dimethylsulfoxide, DMSO December 11, 1991 1992:47 (XIII)
Dioxane August 25, 1982 1983:36 (IV)
revised March 4, 1992 1992:47 (XIII)
Diphenylamine January 25, 1995 1995:19 (XVI)
4,4'-Diphenylmethanediisocyanate April 8, 1981 1982:9 (II)
Dipropylene glycol May 26, 1993 1993:37 (XIV)
Dipropyleneglycol monomethylether December 12, 1990 1992:6 (XII)
Disulfiram October 31, 1989 1991:8 (XI)
Enzymes, industrial June 5, 1996 1996:25 (XVII)
Ethanol May 30, 1990 1991:8 (XI)
Ethanolamine September 4, 1991 1992:47 (XIII)
Ethylacetate March 28, 1990 1991:8 (XI)
Ethylamine August 25, 1982 1983:36 (IV)
Ethylamylketone September 5, 1990 1992:6 (XII)
Ethylbenzene December 16, 1986 1987:39 (VIII)
Ethylchloride December 11, 1991 1992:47 (XIII)
Ethylene December 11, 1996 1997:25 (XVIII)
Ethylene chloride February 29, 1980 1981:21 (I)
Ethylene diamine August 25, 1982 1983:36 (IV)
Ethylene glycol October 21, 1981 1982:24 (III)
Ethylene glycol methylether + acetate June 2, 1999 1999:26 (XX)
Ethyleneglycol monoisopropylether November 16, 1994 1995:19 (XVI)
Ethyleneglycol monopropylether + acetate September 15, 1993 1994:30 (XV)
Ethylene oxide December 9, 1981 1982:24 (III)
Ethylether January 27, 1993 1993:37 (XIV)
Ethylglycol October 6, 1982 1983:36 (IV)
Ferbam September 12, 1989 1991:8 (XI)
Ferric dimethyldithiocarbamate September 12, 1989 1991:8 (XI)
Flour dust December 10, 1997 1998:25 (XIX)
Formaldehyde June 30, 1979 1981:21 (I)
revised August 25, 1982 1983:36 (IV)
Formamide December 12, 1989 1991:8 (XI)
Formic acid June 15, 1988 1988:32 (IX)
Furfural April 25, 1984 1984:44 (V)
Furfuryl alcohol February 13, 1985 1985:32 (VI)
Gallium + Gallium compounds January 25, 1995 1995:19 (XVI)
Glutaraldehyde September 30 1998 1999:26 (XX)
Glycol ethers October 6, 1982 1983:36 (IV)
Glyoxal September 13, 1996 1996:25 (XVII)
Grain dust December 14, 1988 1989:32 (X)
Graphite December 10, 1997 1998:25 (XIX)
Halothane April 25, 1985 1985:32 (VI)
2-Heptanone September 5, 1990 1992:6 (XII)
3-Heptanone September 5, 1990 1992:6 (XII)
Hexachloroethane September 15, 1993 1994:30 (XV)
Hexamethylenediisocyanate April 8, 1981 1982:9 (II)
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Hexamethylenetetramine August 25, 1982 1983:36 (IV)
n-Hexane January 27, 1982 1982:24 (III)
2-Hexanone September 5, 1990 1992:6 (XII)
Hexyleneglycol November 17, 1993 1994:30 (XV)
Hydrazine May 13, 1992 1992:47 (XIII)
Hydrogen bromide February 11, 1998 1998:25 (XIX)
Hydrogen fluoride April 25, 1984 1984:44 (V)
Hydrogen peroxide April 4, 1989 1989:32 (X)
Hydrogen sulfide May 4, 1983 1983:36 (IV)
Hydroquinone October 21, 1989 1991:8 (XI)
Indium March 23, 1994 1994:30 (XV)
Industrial enzymes June 5, 1996 1996:25 (XVII)
Isophorone February 20, 1991 1992:6 (XII)
Isopropanol December 9, 1981 1982:24 (III)
Isopropylamine February 7, 1990 1991:8 (XI)
Isopropylbenzene June 2, 1982 1982:24 (III)
Lactates March 29, 1995 1995:19 (XVI)
Lactate esters June 2, 1999 1999:26 (XX)
Lead, inorganic February 29, 1980 1981:21 (I)
revised September 5, 1990 1992:6 (XII)
Lithium boron nitride January 27, 1993 1993:37 (XIV)
Lithium nitride January 27, 1993 1993:37 (XIV)
Maleic anhydride September 12, 1989 1991:8 (XI)
Manganese February 15, 1983 1983:36 (IV)
revised April 17, 1991 1992:6 (XII)
revised June 4, 1997 1997:25 (XVIII)
Man made mineral fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Mercury, inorganic April 25, 1984 1984:44 (V)
Mesityl oxide May 4, 1983 1983:36 (IV)
Metal stearates, some September 15, 1993 1994:30 (XV)
Methacrylates September 12, 1984 1985:32 (VI)
Methanol April 25, 1985 1985:32 (VI)
Methyl acetate March 28 1990 1991:8 (XI)
Methylamine August 25, 1982 1983:36 (IV)
Methylamyl alcohol March 17, 1993 1993:37 (XIV)
Methyl bromide April 27, 1988 1988:32 (IX)
Methyl chloride March 4, 1992 1992:47 (XIII)
Methyl chloroform March 4, 1981 1982:9 (II)
Methylene chloride February 29, 1980 1981:21 (I)
4,4'-Methylene dianiline June 16, 1987 1987:39 (VIII)
Methyl ethyl ketone February 13, 1985 1985:32 (VI)
Methyl ethyl ketone peroxide February 13, 1985 1985:32 (VI)
Methyl formate December 12, 1989 1991:8 (XI)
Methyl glycol October 6, 1982 1983:36 (IV)
Methyl iodide June 30, 1979 1981:21 (I)
Methylisoamylamine September 5, 1990 1992:6 (XII)
Methyl mercaptane September 9, 1986 1987:39 (VIII)
Methyl methacrylate March 17, 1993 1993:37 (XIV)
Methyl pyrrolidone June 16, 1987 1987:39 (VIII)
Methyl-t-butyl ether November 26, 1987 1988:32 (IX)
revised September 30, 1998 1999:26 (XX)
Mixed solvents, neurotoxicity April 25, 1985 1985:32 (VI)
Molybdenum October 27, 1982 1983:36 (IV)
Monochloroacetic acid February 20, 1991 1992:6 (XII)
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Monochlorobenzene September 16,1993 1993:37 (XIV)
Monomethylhydrazine March 4, 1992 1992:47 (XIII)
Mononitrotoluene February 20, 1991 1992:6 (XII)
Monoterpenes February 17, 1987 1987:39 (VIII)
Morpholine December 8, 1982 1983:36 (IV)
revised June 5, 1996 1996:25 (XVII)
Naphthalene May 27, 1998 1998:25 (XIX)
Natural crystallinic fibers (except asbestos) June 12, 1991 1992:6 (XII)
Nickel April 21, 1982 1982:24 (III)
Nitroethane April 4, 1989 1989:32 (X)
Nitrogen oxides December 11, 1985 1986:35 (VII)
Nitroglycerin February 13, 1985 1985:32 (VI)
Nitroglycol February 13, 1985 1985:32 (VI)
Nitromethane January 6, 1989 1989:32 (X)
Nitropropane October 28, 1986 1987:39 (VIII)
2-Nitropropane March 29, 1995 1995:19 (XVI)
Nitroso compounds December 12, 1990 1992:6 (XII)
Nitrosomorpholine December 8, 1982 1983:36 (IV)
Nitrotoluene February 20, 1991 1992:6 (XII)
Nitrous oxide December 9, 1981 1982:24 (III)
Oil mist April 8, 1981 1982:9 (II)
Organic acid anhydrides, some September 12, 1989 1991:8 (XI)
Oxalic acid February 24, 1988 1988:32 (IX)
Ozone April 28, 1987 1987:39 (VIII)
Paper dust February 7, 1990 1991:8 (XI)
Pentaerythritol November 16, 1994 1995:19 (XVI)
1,1,1,2,2-Pentafluoroethane February 24, 1999 1999:26 (XX)
Pentyl acetate June 14, 2000 2000:22 (XXI)
Peroxides, organic February 13, 1985 1985:32 (VI)
Phenol February 13, 1985 1985:32 (VI)
Phosphorous chlorides September 30, 1998 1999:26 (XX)
Phosphorous oxides February 11, 1998 1998:25 (XIX)
Phthalates December 8, 1982 1983:36 (IV)
Phthalic anhydride September 12, 1989 1991:8 (XI)
Piperazine September 12, 1984 1985:32 (VI)
Plastic dusts December 16, 1986 1987:39 (VIII)
Platinum June 4, 1997 1997:25 (XVIII)
Polyaromatic hydrocarbons February 15, 1984 1984:44 (V)
Polyisocyanates April 27, 1988 1988:32 (IX)
Potassium aluminium fluoride June 4, 1997 1997:25 (XVIII)
Potassium dichromate May 24, 2000 2000:22 (XXI)
Potassium hydroxide Marsh 15, 2000 2000:22 (XXI)
2-Propanol December 9, 1981 1982:24 (III)
Propene September 13, 1996 1996:25 (XVII)
Propionic acid November 26, 1987 1988:32 (IX)
Propylacetate September 14, 1994 1995:19 (XVI)
Propylene glycol June 6, 1984 1984:44 (V)
Propylene glycol-1,2-dinitrate May 4, 1983 1983:36 (IV)
Propylene glycol monomethylether October 28, 1986 1987:39 (VIII)
Propylene oxide June 11, 1986 1986:35 (VII)
Pyridine May 13, 1992 1992:47 (XIII)
Quartz March 13, 1996 1996:25 (XVII)
Resorcinol September 4, 1991 1992:47 (XIII)
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Selenium December 11, 1985 1986:35 (VII)
revised February 22, 1993 1993:37 (XIV)
Sevoflurane May 27, 1998 1998:25 (XIX)
Silica March 13, 1996 1996:25 (XVII)
Silver October 28, 1986 1987:39 (VIII)
Sodium hydroxide August 24, 2000 2000:22 (XXI)
Stearates, metallic, some September 15, 1993 1994:30 (XV)
Stearates, non-metallic, some November 17, 1993 1994:30 (XV)
Strontium January 26, 1994 1994:30 (XV)
Styrene February 29, 1980 1981:21 (I)
revised October 31, 1989 1991:8 (XI)
Sulfur dioxide April 25, 1985 1985:32 (VI)
Sulfur fluorides March 28, 1990 1991:8 (XI)
Synthetic inorganic fibers March 4, 1981 1982:9 (II)
revised December 1, 1987 1988:32 (IX)
Synthetic organic and inorganic fibers May 30, 1990 1991:8 (XI)
Talc dust June 12, 1991 1992:6 (XII)
Terpenes, mono- February 17, 1987 1987:39 (VIII)
Tetrabromoethane May 30, 1990 1991:8 (XI)
Tetrachloroethane June 4, 1997 1997:25 (XVIII)
Tetrachloroethylene February 29, 1980 1981:21 (I)
1,1,1,2-Tetrafluoroethane March 29, 1995 1995:19 (XVI)
Tetrahydrofuran October 31, 1989 1991:8 (XI)
Tetranitromethane April 4, 1989 !989:32 (X)
Thioglycolic acid June 1, 1994 1994:30 (XV)
Thiourea December 1, 1987 1988:32 (IX)
revised June 2, 1999 1999:26 (XX)
Thiram October 31, 1989 1991:8 (XI)
Thiurams, some October 31, 1989 1991:8 (XI)
Titanium dioxide February 21, 1989 1989:32 (X)
Toluene February 29, 1980 1981:21 (I)
Toluene-2,4-diisocyanate April 8, 1981 1982:9 (II)
Toluene-2,6-diisocyanate April 8, 1981 1982:9 (II)
1,1,1-Trifluoroethane February 24, 1999 1999:26 (XX)
Trichlorobenzene September 16, 1993 1993:37 (XIV)
1,1,1-Trichloroethane March 4, 1981 1982:9 (II)
Trichloroethylene December 14, 1979 1981:21 (I)
Trichlorofluoromethane June 2, 1982 1982:24 (III)
1,1,2-Trichloro-1,2,2-trifluoroethane June 2, 1982 1982:24 (III)
Triethanolamine August 25, 1982 1983:36 (IV)
Triethylamine December 5, 1984 1985:32 (VI)
Trimellitic anhydride September 12, 1989 1991:8 (XI)
Trimethylolpropane November 16, 1994 1995:19 (XVI)
Trinitrotoluene April 17, 1991 1992:6 (XII)
Vanadium March 15, 1983 1983:36 (IV)
Vinyl acetate June 6, 1989 1989:32 (X)
Vinyl toluene December 12, 1990 1992:6 (XII)
White spirit December 16, 1986 1987:39 (VIII)
Wood dust June 17, 1981 1982:9 (II)
revised June 25, 2000 2000:22 (XXI)
Xylene February 29, 1980 1981:21 (I)
Zinc April 21, 1982 1982:24 (III)
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Zinc chromate May 24, 2000 2000:22 (XXI)
Zinc dimethyl dithiocarbamate September 12, 1989 1991:8 (XI)
Ziram September 12, 1989 1991:8 (XI)
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